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Bladder cancer (BC) progression is measured by the degree of tumor cell
invasion into the bladder wall and dissemination to distant sites. The study of BC cell
motility will both enable development of anti-invasion therapeutics to limit progression
of early-stage disease and improve our understanding of the metastatic process which
drives patient mortality in BC. BCs display a great deal of intertumoral heterogeneity,
and can be divided into basal and luminal subtypes, which are biologically and clinically
distinct entities. Here, I examine the invasion phenotypes of BC as a function of both
subtype and epithelial to mesenchymal transition (EMT) status. I studied the impact of
Src inhibition on the motility of luminal and basal cell lines. My research demonstrates
that while both luminal and basal models exhibit comparable cell signaling phenotypes
following exposure to the Src Family Kinase (SFK) inhibitor AZD0530, only luminal
models are sensitive to the anti-invasive effects of the compound. I also explore the
correlation between the developmental program, EMT, and invasion in a panel of BC
cell lines. Models could be broadly categorized as epithelial or mesenchymal, with no
significant difference in invasion capacity observed between the two groups. However,
the presence of partial EMT did predict invasion within the epithelial clade, with highly
epithelial models being substantially less invasive than those exhibiting a hybrid
phenotype. The studies detailed here provide rationale for the development of
AZD0530 as an anti-invasive agent in BC and evidence for the role of EMT in BC
invasion.
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CHAPTER 1
BACKGROUND AND SIGNIFICANCE

1

Bladder Cancer is a Disease of Invasion
Bladder cancer is a disease in which tumor stage, and therefore clinical decision
making, is tied to invasion. These tumors arise in the urothelium, the internal epithelial
lining of the bladder. Tumors that remain confined to the urothelium or lamina propria
(stage pT1 or lower) are characterized as non-muscle invasive bladder cancer
(NMIBC). These tumors are generally managed with transurethral resection of bladder
tumor (TURBT), and intravesicular therapies such as bacilli Calmette-Gurein (BCG)1.
The primary clinical concern in NMIBC is progression via local invasion to muscleinvasive bladder cancer (MIBC). MIBCs (stage pT2 or greater) are at much greater risk
for metastatic spread and death, and they are therefore managed more aggressively.
Standard-of-care for MIBC is definitive therapy involving neo-adjuvant cisplatin-based
combination chemotherapy, followed by radical cystectomy or trimodal therapy with
chemoradiation1. These regimens are associated with higher morbidities than those
used in the NMIBC setting, with surgery associated mortality a major concern1.
The side-effects and risks of this aggressive clinical strategy are justified by the
lethal threat posed by metastatic bladder cancer. The primary causes of cancer-related
death are complications associated with metastasis2 and bladder cancer is no
exception. While relative five-year survival in patients with localized disease is 69.2%,
among patients with distant metastasis relative five-year survival drops to 5.5%3. The
potential benefits of an improved understanding of bladder cancer invasion are
therefore two-fold. Preventing progression from NMIBC to MIBC, which necessitates
systemic therapies and high-morbidity surgery, is a major clinical priority. Anti-invasive
agents, therapeutics that limit progression by preventing further invasion into the
2

bladder wall, could delay or eliminate the need for radical cystectomy in high-risk
NMIBC patients. In those who already have MIBC, an improved understanding of
dissemination may lead to strategies to limit metastasis or manage metastatic disease.
Bladder Cancers Form Intrinsic Subtypes
Beyond staging by invasion status, bladder tumors can be divided into intrinsic
subtypes. Analysis of bladder cancer clinical samples by micro-array4,5and later RNA
sequencing6 identified two main subsets of tumors, basal and luminal, named for their
expression of urothelial differentiation markers. The subtypes display different
biological and clinical characteristics, making them related but distinct disease entities.
Basal cancers (fig 1a) are enriched for markers associated with the basal layer of the
urothelium, including keratins-5(KRT5), -6(KRT6), and -14(KRT14)4–6. They also exhibit
gene expression indicative of active ΔNp63, a known basal transcription factor5.
Luminal tumors (fig 1b) show upregulation of markers characteristic of luminal urothelial
cells, including GATA3, FOXA1, and keratin-20 (KRT20). Gene expression analysis of
luminal cancers suggests activation of the transcription factor peroxisome proliferator
activated receptor-gamma (PPARG), including high expression of PPARG target gene,
FABP45.
There are major differences in invasive behavior among bladder cancer
subtypes. Luminal tumors are strongly enriched among NMIBC7 while comprising about
half of MIBCs4. Basal tumors are more likely to be muscle-invasive7 and metastatic5 at
presentation and can therefore be considered more aggressive than their luminal
counterparts. However, luminal tumors also commonly metastasize4–6, making them
also potentially lethal. The underlying cause of these clinical trends is unknown, and is
3
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Figure 1 Bladder cancers can be divided into different subtypes. (A) Basal bladder
cancers exhibit expression of canonical basal urothelial markers. While EMT marker positivity
is a trait common across basal cancers, degree of mesenchymal differentiation distinguishes
more epithelial basal-squamous tumors from rare, sarcomatoid tumors. (B) Luminal bladder
cancers exhibit expression of canonical luminal urothelial markers. They can be further
subdivided into less aggressive luminal papillary tumors and stromal cell enriched luminal
infiltrated or p53 like tumors.
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an active area of interest in the research community. Differences in invasive and
metastatic behavior have interesting implications for the development of drugs targeting
dissemination in bladder cancer. Their high prevalence among NMIBC cases makes
luminal tumors ideal targets for progression-disrupting, anti-invasive agents, while
therapeutics targeting both subtypes are needed in the metastatic space.
Src as an Anti-Invasive Drug Target in Bladder Cancer
A particularly interesting drug target in bladder cancer is the intracellular kinase,
Src. Src relays signals from transmembrane receptor proteins, including growth factor
receptors and integrins8. Through its interactions with binding partner and kinase
substrate Focal Adhesion Kinase (FAK), Src regulates cell substrate adhesion and cell
migration9,10. Src has also been found to drive cancer cell motility and metastasis in
multiple tumor types11,12. Its established role in invasion and metastasis, combined with
the availability of clinical grade inhibitors make Src an attractive anti-invasive target.
However, the role of Src in bladder cancer invasion and metastasis is controversial.
Several studies suggest Src actually inhibits invasion in bladder cancer, both by
activating metastasis suppressor, RhoGDI213, and by counteracting the activity of
metastasis promoter, Caveolin-1 (Cav-1)14. Given the ambiguity of the relationship
between Src and invasion in these tumors, and the potential clinical utility of Src
inhibition, further study of Src in bladder cancer is warranted.
Src Family Kinase Structure
Src (fig 2) is a nonreceptor tyrosine kinase and titular member of the Src Family
Kinases (SFKs), which consists of 9 members including Src, Yes, Fyn, Fgr, Lck, Blk,
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Hck, Lck, Lyn, and Frk15. While expression of the majority of SFKs is restricted to cells
of hematopoietic lineage, Src, Fyn, and Yes are expressed ubiquitously across tissue
types15. SFKs share a common structure, consisting of a unique N-terminal SH4
domain, highly conserved, ligand binding SH2 and SH3 domains, and a kinase (SH1)
domain16. This high degree of sequence homology amongst the family members lends
itself to signaling redundancies, and has led researchers to study Src in models such
as SFY fibroblasts, which lack functional copies of Src, Fyn, and Yes17.
SFK activity is tightly regulated by tyrosine phosphorylation, which serves to
either augment or inhibit kinase activity. Among activity-promoting phosphorylation
events, the most well-characterized is autophosphorylation at Y416 (Src- standard
avian numbering) in the activation loop18. Phosphorylation of Y527 (Src- standard avian
numbering) plays an opposite role, strongly suppressing SFK activity by inducing a
conformational shift involving the SH2 and SH3 domains19. The result is the formation
of a molecular clamp which locks the kinase domain in an inactive state. This
intramolecular interaction is a major mechanism by which SFK activity is inhibited.
Induction or disruption of this inhibitory state is controlled by a series of kinases,
phosphatases, and protein ligands which dynamically regulate SFK activity in response
to extracellular cues and internal feedback mechanisms.
Src Family Kinase Regulation
C-terminal Src kinase (Csk) is a major inhibitor of SFKs that acts through
phosphorylation of the Y527 inhibitory residue20. Under basal conditions Csk remains
cytosolic, functionally sequestered from active SFKs, which localize to the plasma
membrane. In order to inhibit SFKs, Csk must be recruited to the membrane through
6

Figure 2 Src Family Kinases share a common structure. SFKs exhibit a characteristic four
domain structure including a unique SH4 domain, SH3 and SH2 ligand binding domains, and
an SH1 kinase domain. The autophosphorylation site (Y416 in Src), used as a marker of SFK
activation, is located in the kinase domain. Another phosphorylation site (Y527 in Src) is
located on the C-terminal tail. When phosphorylated, this residue reduces kinase activity by
inducing an auto-inhibitory protein confirmation.
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interactions with proteins like Csk-binding protein (Cbl) or Cav-121. These translocation
events are often induced by Src or SFK activity, serving as part of a negative feedback
loop that downregulates SFK activation21. Csk homology kinase (Chk) is also
implicated in Y527 phosphorylation22,23. Unlike Csk, Chk is also able to inhibit SFKs
through a non-catalytic, protein-protein interaction, which limits SFK kinase activity24.
Multiple phosphatases have been suggested to dephosphorylate Y527, thereby
countering the activities of Csk and Chk, to activate Src and other family members.
Research in human breast cancer models has implicated protein tyrosine phosphatase
1B (PTP1B) in activating Src through this mechanism25. SHP-1 has also been
implicated as a Y527 phosphatase26. Phosphatase SHP-2 also promotes Src and SFK
activation but does so through an indirect mechanism that limits Csk recruitment to
sites of SFK activity27.
Although dephosphorylation of Y527 is a major mechanism of SFK activation, it
is not necessarily a prerequisite for disruption of the intramolecular interactions that
limit kinase activity in the family. Binding to high-affinity protein ligands can also disrupt
the inhibitory confirmation, allowing SFKs to act on protein substrates16. Direct
interaction with the platelet-derived growth factor receptor (PDGFR)28 or FAK15 can
induce Src activation through this mechanism.
Upstream Activators of Src- FAK, Integrins, and Growth Factor Receptors
A variety of signaling proteins are able to activate Src (fig 3). Of particular
importance in the context of migration are Src’s interactions with FAK. Src and FAK
have a unique, reciprocal relationship in which FAK serves as both an upstream
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activator of Src and a downstream signaling substrate. Integrin engagement results in
FAK autophosphorylation at Y397, creating a high affinity docking site for Src 9. Src
binding to FAK disrupts the intermolecular interactions that lock Src’s kinase domain in
an inactive state29. In turn, Src phosphorylates FAK at multiple sites, enhancing FAK’s
kinase activity and substrate binding capacity30,31. The importance of this relationship is
well-illustrated by the comparable phenotypes of Src-deficient and FAK-deficient
models. Both Src-/-32 and FAK-/-33 fibroblasts fail to display the cell spreading behavior
of wildtype fibroblasts. FAK-/- and Y397F FAK cells display comparable reductions in
adhesion complex turnover as Src-deficient cells34. Similar deficiencies were observed
in cells lacking the downstream substrate of Src and FAK, p130CAS 34.
Growth factor receptors are also major drivers of Src signaling. A diverse array
of growth factor receptors have been reported to activate Src and other family
members including EGFR8, FGFR-135, IGF-1R36, and PDGFR28. Interactions between
Src and growth factor receptors may be direct, as in the previously noted example of
PDGFR28. They can also require intermediaries, as observed by Goi et al. 2000, who
found that EGFR-mediated activation of Src required Ral-GTPase37. Receptor signaling
through Src and other SFKs feeds into and promotes a variety of processes relevant to
tumor biology including proliferation, survival, and, cell motility38. The interactions
between growth factor receptors and the Src family are also bidirectional. Src can
directly phosphorylate EGFR on tyrosine residues that are different from those
phosphorylated after ligand binding39. This phosphorylation likely amplifies EGFR
signaling and is hypothesized to be a common mechanism by which SFKs reinforce

9

Figure 3 Src is part of a complex signaling network. Src is activated by both growth factor
receptors and FAK-mediated integrin signaling. Following activation, Src adopts an active
signaling confirmation, allowing it to take part in a variety of motility associated processes.
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growth factor receptor activity38. However, Src is also a mediator of receptor
internalization, promoting the endocytosis of EGFR following ligand stimulation40,
suggesting that Src can both promote and disrupt growth factor signaling depending on
cellular context.
Integrins are important components of the migration machinery, making their
links with Src highly relevant to cell motility. Integrins bind to extracellular matrix (ECM)
substrates, activating Src and driving it to phosphorylate motility-relevant targets,
including Fak, p130Cas, and Paxillin17. Through these substrates, Src regulates
cytoskeletal dynamics as well as integrin-mediated adhesion to the ECM29. Both of
these processes are discussed in more detail below. It would be a mistake to consider
growth-factor and integrin-mediated Src signaling in isolation from one another. Src
serves as a bridge between these two networks, integrating mechanical and soluble
factor signals. In response to integrin ligand binding, Src enhances growth factor
receptor activation39. In turn, growth factor signaling can, through Src, promote
association between integrins and signaling partners like FAK41. It is by assimilating
inputs from these two systems that Src is able to control the multiple processes that
drive migratory behavior.
Tools Used to Study Src- Specificity and Redundancy
Because Src is heavily regulated by post-translational modification,
overexpression of constitutively-active Src, rather than wildtype Src, is often used by
researchers to study the effects of activated Src. The most common versions of
constitutively-active Src are v-Src and Y527F c-Src. Derived from an avian sarcomainducing virus, v-Src lacks a c-terminal tail, including the Y527 residue. It is therefore
11

not subject to the inhibitory confirmation induced by phosphorylation of c-Src Y52742.
Y527F c-Src retains the c-terminal tail but contains a substitution at the negative
regulatory residue, thus making it unresponsive to mechanisms that limit wildtype c-Src
activation19.
Disruption of Src signaling is commonly achieved through the use of chemical
inhibitors including PP1, PP2, AZD0530, dasatinib, and bosutinib. While the effects of
these inhibitors are often attributed specifically to Src inhibition, they inhibit all SFKs
with a high degree of potency43,44. I therefore use the term SFK inhibitor rather than Src
inhibitor when discussing these compounds. The intra-family promiscuity of these drugs
and the possibility of signaling redundancy among SFKs makes it impossible to confirm
that Src inhibition alone is the driver of treatment effects. Confirming that Src is
specifically responsible for a given phenotype requires genetic means. However, even
ostensibly more specific methods of Src inhibition can theoretically disrupt signaling of
other family members. For example, overexpression of dominant negative kinase-dead
Src could partially inhibit other SFKs by blocking binding to common signaling
substrates. Given this limitation, I have attempted to specify whether cited sources
demonstrate that Src, or SFKs more generally, are responsible for a described
phenomenon.
Src and SFK Regulation of Migration- Actin Dynamics and Focal Adhesion
Src orchestrates motility through regulation of multiple, spatially-distinct cellular
processes that must be properly coordinated (fig 3). At the leading edge of the cell,
polymerization of branched actin filaments of the lamellipodia drives the cell body
forward. Construction of these filaments is performed by the Arp2/3 complex, which
12

nucleates new branches off of existing actin filaments. Activity of the Arp2/3 complex is
driven by Src signaling through the Rho family GTPases, Rac1 and Cdc4229. Loss of
Src severely disrupts lamellipodia formation. Embryonic fibroblasts derived from Src -/mice fail to produce lamellipodia in response to growth factor stimulation 45. Additionally,
SYF fibroblasts, but not Fyn-/- Yes-/- fibroblasts (containing wildtype Src) exhibited
deficiencies in lamellipodia formation when plated on fibronectin-coated coverslips46.
At the cell rear, Src, along with other members of the Src family, play important
roles in the turnover of focal adhesion (FA) complexes, which allow for retraction of the
trailing cell edge. FA’s are comprised of integrins and associated scaffolding and
signaling proteins that cluster upon binding to ECM substrate. These clusters serve as
important links between the actin cytoskeleton and the extracellular environment,
allowing cells to generate the traction necessary for motility47. Transfection with a
dominant negative Src or treatment with Src family kinase inhibitor PP2 dramatically
slows adhesion turnover34. Additionally, rescue experiments using wildtype Src in SYF
fibroblasts restores adhesion turnover rates34, demonstrating the particular importance
of Src in this process.
Src and SFK Regulation of Migration- Matrix Remodeling
Migration and invasion through complex ECM environments often require pericellular proteolysis to produces pores of adequate size for nuclear translocation 48. Src
is an important driver of matrix remodeling and enables this process by promoting the
activity of extracellular proteases and the formation of degradation-associated cellular
structures. Early evidence for Src’s role in ECM degradation came from studies of Src
knockout models. Src null mice display extensive osteopetrosis, a disorder
13

characterized by inadequate breakdown and resorption of bone 49. This phenotype is
driven by defects in osteoclast activity50, cells which normally express high levels of
membrane associated Src51. It was later discovered that osteoclasts lacking Src exhibit
deficiencies in the formation of matrix degrading structures known as podosomes 52.
The podosomes that did form in this model were fewer in number and failed to properly
mature. Src kinase activity was found to be essential to normal podosome formation, as
a kinase-dead Src was unable to revert these cells to a wildtype phenotype52.
Podosomes are actin-rich cellular protrusions that promote ECM breakdown via
localization of both soluble and membrane-bound proteases, particularly those from the
matrix metalloprotease (MMP) family53. The term invadopodia is used for podosomelike structures on malignant cells. However, it is unclear whether invadopodia differ
from podosomes in any meaningful way, so the terms are often used
interchangeably53. The term podosome was originally coined by Tarone et al. 1985 to
describe structures formed following v-Src induced transformation of fibroblasts54. Later
work in SYF fibroblasts found re-expression of c-Src is required for podosome
formation, demonstrating that non-transforming variants of Src are able to induce
podosome assembly55. Growth factor and integrin signaling, both upstream of Src,
induce podosome or invadopodia formation. Yamaguchi et al. 2005 found that EGFR
drove invadopodia formation in an adenocarcinoma model56. Destaing et al. 2010
found expression of integrin beta-1 was required for formation of what they called
invadosomes, a consensus term for podosomes and invadopodia57. Src is implicated in
invadopodia formation in a number of cancer model systems. Mader et al. 2011 found
that Src localizes to invadopodia in the MDA-MB-231 breast cancer cell line. Src siRNA
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treatment was sufficient to disrupt invadopodia maturation in this model 58. In multiple
melanoma cell lines, hypoxia increases both SFK Y416 phosphorylation and
invadopodia formation in a hypoxia inducible factor (Hif) dependent manner 59. In
transformed mammary epithelial cells, SFK inhibitor SU6656 prevented Twist induced
Src activation and invadopodia formation60. Taken together these studies suggest Src
drives invadopodia formation in multiple tumor types and in response to a variety of
signals.
Though MMP mediated proteolysis is a major mechanism by which podosomes
and invadopodia promote cell motility, Src’s role in MMP activity has also been
extensively studies outside of the podosome/invadopodia context. Early work with v-Src
firmly established the link between Src activity and extracellular proteolysis. v-Src
transfection drives promoter activity of MMP-9 in HT1080 fibrosarcoma cells61 and
MMP-1 in a rabbit fibroblast model62. Kadono et al. 1998 found v-Src transformation of
MDCK cells results in increased MT1-MMP expression62. Later work confirmed the
ability of human c-Src and other SFKs to drive cancer MMP expression using both
chemical and genetic means. Treatment with dasatinib limited secretion of MMP-9 in
DU145 prostate cancer cells63. Treatment with PP2 or SU665 had similar effects in
MCF7 breast cancer cells64. Park et al. 2006 demonstrated that dominant-negative Src
and PP2 treatment reduced both basal and ionizing radiation-induced MMP-2 secretion
in multiple glioma cell lines65.
Src and SFK Regulation of Migration- EMT
Src can also promote cell motility by activating the developmental program,
EMT. EMT involves a shift from a largely epithelial phenotype to a more migratory,
15

fibroblast-like state. This change is associated with downregulation of canonical
epithelial markers, like e-cadherin, and upregulation of mesenchymal markers, like
vimentin66. EMT has been broadly implicated in cancer invasion and metastasis across
a wide swath of tumor types67–69. A more detailed explanation of EMT and the
controversy surrounding its role in tumor biology can be found elsewhere in this
document. Early work showed that activation of v-Src induced EMT in MDCK cells as
measured by both morphological assessment and the loss of e-cadherin cell-cell
junctions70. Using a Y527F c-Src expression construct, Avizienyte et al. 2002 found
that in KM12C colon cancer cells, Src disrupted e-cadherin mediated cell-cell adhesion
and promoted formation of peripheral adhesion complexes, both hallmarks of EMT70.
Src’s effects on e-cadherin junction disassembly were reversed by expression of
mutant FAK that lacked tyrosine residues typically phosphorylated by Src, suggesting
interactions between Src and FAK were required for EMT70.
Rather than genetic manipulations, later studies often relied on inhibitors of the
Src family to prevent or reverse EMT. Using the compounds PP2 and AZD0530, Kao et
al. 2014 suggested that Src drives EMT in VCap and PC3 prostate cancer cells through
repression of the anti-EMT mir30a71. Joannes et al. 2014 showed that siRNA-mediated
knockdown of pro-epithelial factor Fhit induces EMT in human bronchial cells.
Treatment with PP1 prevented EMT in this model system, reversing upregulation of the
EMT transcription factor Slug and the mesenchymal marker vimentin72.
However, studies wholly reliant on chemical inhibition to demonstrate Src’s role
in EMT should be interpreted cautiously. As early as 2006, it was demonstrated that the
commonly used PP1 compound directly inhibits Transforming Growth Factor-Beta
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Receptor 1 (TGFBR1)73. Subsequent research demonstrated that many popular Src
inhibitors, including both dasatinib and AZD0530, are potent inhibitors of TGFBR143,44.
TGFBR1 is part of the receptor complex for the cytokine, TGF-B, which is an
established driver of EMT74. Activation of the TGFBR1 signaling complex induces
phosphorylation of SMAD2 and SMAD3, which in turn bind to their co-Smad, SMAD475.
These SMAD complexes translocate into the nucleus and directly induce transcription
of EMT-associated genes, including Snail76 and ZEB1/SIP177. SMAD complexes also
act in concert with other transcriptional regulators to repress epithelial markers, most
notably the cell junction protein e-cadherin78. Thus, while the anti-EMT effects of Src
inhibitors may be attributable to on-target activity, they may also be due in part or in
whole to TGFBR1 inhibition.
It is clear that Src can modulate EMT in certain cases. Early studies which relied
on genetic means to study Src clearly demonstrated the ability of active Src to induce
EMT in certain models. Additionally, more recent work has validated results obtained
by chemical Src inhibition via orthogonal means. Fang et al. 2017 reversed EMT in
highly mesenchymal SK-OV3 and OVCAR5 ovarian cancer cell lines by co-treating with
AZD0530 and a MEK inhibitor79. They then confirmed the roles of Src and MEK in this
process by inducing EMT in epithelial ovarian cancer models OVCAR3 and HEC1A via
transduction with constitutively active Src and MEK expression constructs79. The
question is not whether Src is able to induce EMT, but how common such an event is.
Studies attempting to investigate this topic must be carefully designed, ideally
employing multiple methods to assess whether Src signaling regulates EMT in a given
context.
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Src Drives Tumor Invasion and Metastasis
Unsurprisingly, given the intimate involvement of Src and other family members
in the fundamental mechanics underlying cell motility, as well as higher level processes
like invadopodia-mediated matrix remodeling and EMT, Src has been strongly
implicated in cancer cell invasion and metastasis. The literature on Src and tumor
dissemination is extensive. Studies demonstrating the ability to promote spread span a
variety of tumor types. The methods employed are also widely varied, ranging from
endogenous and chemical SFK inhibitors, to overexpression of wildtype and
constitutively active forms of Src. Of particular interest are studies that use in vivo
models, which show that even within a physiological context, Src plays an important
role in invasion and metastasis. Cumulatively, these studies demonstrate that, across
systems, Src is a central driver of metastatic spread.
An important caveat to understand when considering mechanistic studies of Src
and invasion is the potential confounding effect of anti-proliferative activity. This factor
is particularly relevant when examining the effects of Src disruption in vivo. In some
models, no impact on tumor growth is observed when Src is inhibited, making
reductions in invasion or metastasis easily to attributable to disrupted motility. In other
cases, for example, following treatment with SFK inhibitors, decreases in growth make
results more difficult to interpret. These phenotypes may be caused by later entry into
the metastatic cascade, or delayed outgrowth of micro-metastases, rather than direct
effects on motility. Later studies account for this possibility through novel study designs
that isolate anti-proliferative and anti-invasive activity. Results suggest that, at least in
tumor models tested, disruption of Src signaling primarily results in decreased invasion
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and metastasis. Inhibition of other SFKs likely yield the anti-proliferative effects
observed when pan-SFK inhibitors are used.
Src Drives Tumor Invasion and Metastasis- Initial Associations
Early studies linking Src to metastasis were correlative in nature, comparing Src
levels in metastatic and non-metastatic patient samples. Talamonti et al. 1993 explored
Src activity and expression in a series of colon cancer specimens. They found
enrichment for Src in liver metastases relative to primary tumors. Synchronous samples
taken from the one patient exhibited the same pattern, suggesting cells expressing
higher levels of Src have enhanced metastatic potential80. Termuhlen et al. 1993
obtained identical results when examining extra-hepatic colon cancer metastases81.
Again, Src was enriched in metastatic lesions suggesting that, rather than being a
promoter of liver metastasis, Src is a general driver of dissemination. Work in colon
cancer cell lines supported this hypothesis. Mao et al. 1997 sought to determine Src
protein and phospho-protein expression in highly metastatic KM12SM and KM12L4A
cells and poorly metastatic KM12C cells. Metastatic potential in these models positively
correlated with Src expression82. The metastatic lines also exhibited more pronounced
increases in Src phosphorylation in response to EGF stimulation, suggesting these
cells were also primed to activate Src in response to external stimuli82.
Src Drives Tumor Invasion and Metastasis- Mechanistic Studies
Later studies took a mechanistic approach, providing more conclusive evidence
that Src drives dissemination by promoting or disrupting Src activity in a variety of in
vitro and in vivo models. Nakagawa et al. 2000 furthered earlier work in colon cancer
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by overexpressing a negative regulator of SFKs, CSK, in NL-17 cells. In vitro, CSK
overexpression diminished Src activity, reduced active MMP-2 expression, and
decreased Matrigel invasion83. Lung colonization in an experimental metastasis model
was also reduced. While parental tumors implanted subcutaneously invaded the
peritoneal cavity, CSK overexpressers failed to do so83. Tumors from parental and CSK
cells grew at comparable rates, suggesting that reductions in invasion, rather than
slower growth, were responsible for the observed phenotype83.
One of the earliest efforts to directly explore the role of Src in dissemination
employed the invasive rat bladder cancer cell line, NBT-II. NBT-II cells overexpressing
either a dominant negative variant of Src or CSK exhibited marked reductions in lymph
node metastasis84. Metastases that did arise appeared to originate from cells which
had lost transgene expression, as they were no longer resisting the selection agent,
geneticin. Furthermore, metastases derived from parental NBT-II cells exhibited
increased Src expression, and increased phosphorylation of Src targets cortactin and
FAK84. This result suggested heterogeneity within the parental model, with Src
expression conferring a selective advantage during invasion and metastasis. The
authors suggested that, at least in NBT-II, Src drives metastasis by promoting a partial
EMT. Overexpression of wildtype or Y527F Src induced a mesenchymal-like phenotype
in cultured cells, while dominant negative Src and CSK cells exhibited a high degree of
epithelial differentiation, patterns which were largely recapitulated in vivo84.
Myoui et al. 2003 studied the impact of Src on breast cancer dissemination using
MDA-MB-231 cells. Overexpression of a kinase-dead variant of Src decreased
experimental bone metastasis following intracardiac injection and experimental lung
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metastasis following tail vein injection. Y527F Src expression promoted the formation of
larger bone metastases85. The differences seen in Y527F Src cells may have been due
at least in part to differences in proliferation, rather than metastatic ability. They formed
larger tumors following orthotopic injection than empty vector or kinase dead Src cells.
However, kinase dead Src cells had similar primary tumor weights and mitotic indexes
to empty vector cells, demonstrating that non-proliferative effects were responsible for
anti-metastatic effects of Src disruption85.
Using a stable Src RNAi expression model, Trevino et al. 2006 sought to
determine whether Src drives tumor growth or metastasis in L3.6pl pancreatic cancer
cells using an orthotopic xenograft model. In vitro, Src siRNA had no effect on
proliferation, and mice injected with various Src siRNA cell inoculums developed
tumors at a comparable efficiency to vector control and parental cells. At larger cell
inoculums, Src siRNA cells formed slightly smaller tumors than controls, though these
differences were not statistically significant11. The authors attributed this effect to
reduced angiogenesis, rather than reduced proliferation. The effects on dissemination,
however, were significant. Across all conditions, rates of lymph node and liver
metastasis were substantially reduced11. Use of an orthotopic model, the gold standard
for metastasis studies, makes these results particularly significant. Earlier studies relied
primarily on either experimental metastasis models, which fail to recapitulate the full
metastatic cascade, or subcutaneous implantation, which yields a tumor
microenvironment that is not representative of the model’s site of origin. Additionally,
the lack of effects on proliferation suggest the Src phenotype is driven by changes in
motility, though an impact of the anti-angiogenic effects in the Src siRNA tumors cannot
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be ruled out. Interestingly, dasatinib treatment replicated the anti-metastatic results
obtained with siRNA cells and significantly inhibited tumor growth11, raising the
possibility that another Src family member, also inhibited by dasatinib, is responsible for
the anti-proliferative effects seen here and in other SFK inhibitor studies.
A follow-up study by the same group, this time employing the prostate cancer
model PC3, provided further evidence that Src is primarily a driver of dissemination,
while other SFKs are important to proliferation. siRNA mediated knockdown of Src had
a minuscule, though statistically significant, impact on proliferation of PC3 cells in
vitro12. However, knockdown of the SFK Lyn, chosen for its role in normal prostate
morphogenesis, substantially decreased proliferation12. Knockdown of Src substantially
decreased Matrigel invasion, while results for Lyn knockdown were not reported12. In
vitro treatment with dasatinib phenocopied the effects of Src and Lyn knockdown,
strongly inhibiting both proliferation and invasion. Experiments in PC3 orthotopic
models recapitulated these results, with dasatinib substantially decreasing both tumor
growth and lymph node positivity12. In order to control for confounding anti-proliferative
effects, the authors also allowed dasatinib-treated tumors to grow to the same sizes as
controls before examining dissemination. Stark differences in lymph node metastasis
remained, demonstrating that both anti-proliferative and anti-invasive effects were
responsible for the dasatinib phenotype12. Taken together with the in vitro data and the
results of Trevino et al. 2006, this study strongly supports a model wherein Src is a
major driver of invasion and metastasis while other SFKs, are responsible for the antigrowth effects observed with pan-SFK disrupting techniques.
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Clinical Development of SFK Inhibitors- Optimism and Disappointment
Agents targeting the Src family have been the subject of major investments by
drug developers in terms of both time and financial resources. Though numerous SFK
inhibitors have been used in preclinical studies or as research tools, only three
compounds have reached widescale clinical testing for oncology indications. Those
agents are dasatinib86, developed by Bristol Myers Squibb, AZD0530 (saracatinib)87,
developed by Astra-Zeneca, and bosutinib88, developed by Pfizer. All three are orally
available, competitive ATP binding domain inhibitors. These compounds have been
used, and in the case of dasatinib, approved for the treatment of chronic myeloid
leukemia, due to their activity against Abl kinase44,89. However, the majority of trials
where Src and other family members were the intended drug targets took place in solid
tumors, notably prostate90,91 and breast92 cancers.
Set against the backdrop of years of basic science research, these compounds
produced a great deal of excitement as they entered clinical testing. Many were
optimistic, given the wealth of data suggesting that SFKs are major drivers of tumor cell
proliferation and cell survival38 that SFK inhibitors would prove active in a variety of
tumor indications. SFKs also signal through growth factor receptors38, which are
themselves oncology drug targets. These compounds therefore also promised new
avenues to disrupt oncogenic growth factor signaling and possibly a way to circumvent
resistance mechanisms to receptor targeted agents. Potentiation of the tumor killing
effects of traditional chemotherapeutics was also a possible application 93,94. Trials
involving dasatinib, AZD0530, and bosutinib were largely meant to examine cytotoxic or
cytostatic potential, rather than any anti-invasive activity. Thus, the results of those
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trials, while disappointing, must be viewed in light of that distinction. Additional studies,
involving different patient populations and measuring different endpoints are required to
evaluate SFK inhibitors as anti-invasives.
Initial phase I monotherapy trials of dasatinib and AZD0530, which reach solid
tumor clinical testing prior to bosutinib, demonstrated these compounds to be welltolerated and capable of inhibiting Src signaling in patients. Demetri et al. 2009 found
dasatinib to have limited toxicity, with most side-effects manageable through pauses in
treatment and dose reductions95. Neither disruptive cardiac toxicity, nor
immunosuppressive effects, suggested by preclinical studies and clinical experience
with other kinase inhibitors, occurred in patients on study95. AZD0530 also had a
favorable safety profile. Minimal myelosuppressive activity was seen, and the authors
noted that adverse events were mostly managed without reductions in dose or
withdrawal from the study96. Given the minimal toxicity in study participants, authors of
both studies recommended further monotherapy trials with dasatinib and AZD053095,96.
Despite continued optimism, there were early signs that SFK inhibitors would not
meet the expectations set by preclinical studies. Neither the dasatinib study nor the
AZD0530 study recorded a single complete or partial response among trial
participants95,96. The best response observed in either trial was stable disease, which in
both cases occurred in less than 20% of patients95,96. In reference to this outcome,
Demetri et al. 2009 note that participants in the dasatinib study were heavily pretreated,
a population less likely to respond to any cancer therapeutic95. They were also highly
heterogenous, representing a wide array of tumor indications, only a subset of which
may have been likely responders to dasatinib. The same was true for the AZD0530
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study96. This interpretation is reasonable and not uncommon in phase I oncology
clinical trials. These studies are designed to test the safety of therapeutics and
establish a maximum tolerated dose. Efficacy is often a secondary endpoint that need
not be met when considering a recommendation to progress to larger, phase II clinical
trials.
Results of the phase II monotherapy trials though, were largely disappointing. Yu
et al. 2009 measured the impact of dasatinib on metastatic, castration resistant
prostate cancer. Though encouraging reductions in markers associated with bone
disease were noted, stable disease was the best clinical outcome observed among trial
participants90. A similar phase II trial of AZD0530 monotherapy failed to meet
predesignated endpoints for reductions in prostate specific antigen or progression-free
survival97. Additional studies also failed to find benefit in the use of SFK inhibitors as
stand-alone agents. In a phase II trial in unselected melanoma patients, dasatinib
yielded only a 14% response rate when tumors harboring c-Kit mutations, which
dasatinib inhibits, were excluded98. An AZD0530 trial in metastatic, hormone receptornegative breast cancer was discontinued for futility after the treatment of only nine
patients, none of whom achieved a prolonged response or prolonged stable disease 92.
These and other negative trials demonstrated that SFK inhibitors, at least as
monotherapies, do no generate responses in the majority of solid tumor patients. It was
likely with these results in mind that the phase I monotherapy study of bosutinib,
published in 2012, included a more stringent efficacy endpoint. When this endpoint was
not met, the authors recommended that future trials include bosutinib as part of a drug
combination, rather than as a stand-alone treatment99.
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Following failure in monotherapy trials, SFK inhibitors moved into a variety of
combination therapy studies, with the goal of augmenting responses to agents already
considered standard-of-care. These included cytotoxic agents, such as gemcitabine
and docetaxel, as well as targeted therapies like the EGFR inhibiting monoclonal
antibody, cetuximab. These combinations were rational, backed by understanding
developed in the preclinical setting of Src’s role in promoting survival signaling and
resistance to growth factor receptor inhibitors93,94,100. Unfortunately, as was the case in
the monotherapy studies, preclinical observations failed to translate into clinical activity.
Across multiple studies, SFK inhibitors did not improve therapeutic efficacy of existing
treatments. One of the largest studies was a double-blind, phase III trial examining
dasatinib in combination with docetaxel versus docetaxel and placebo in a cohort of
men with chemo-naïve metastatic prostate cancer. No improvement in overall survival
was found with the addition of dasatinib91.
Clinical Development of SFK Inhibitors- New Possibilities
Despite the numerous setbacks experienced during the clinical development of
SFK inhibitors, there is still a potential utility for these agents, provided that they are
applied to the appropriate patient populations in the appropriate contexts. Despite
dozens of clinical trials and the massive body of evidence for the role Src and other
SFKs play in cell motility, the anti-invasive properties of these agents have never been
adequately examined in patients. Oncology clinical trials are generally designed to
measure cytotoxic and cytostatic effects of new drugs, rather than anti-invasive activity.
Response rates are measured in part by changes in the size of existing lesions, a result
of cell proliferation and cell death. The emergence of newly-detectable lesions is also
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taken into account. However, it is impossible to differentiate between the spread of
tumor cells to new sites and outgrowth of pre-existing, but previously undetectable,
micro-metastases. The patient populations that took part in the SFK inhibitor clinical
trials, as is commonly the case in oncology studies, largely consisted of individuals with
advanced disease, who were quite likely to have micro-metastatic lesions in addition to
detectable macro-metastases. Thus, while these studies could effectively test the
hypothesis that SFK inhibitors are cytotoxic or able to potentiate the cell killing capacity
of other agents, they were entirely unsuited to measure effects on invasion and
metastasis.
Indeed, disrupting invasion was never the goal of these trials. Limiting further
spread is of little utility if therapy fails to inhibit the growth of pre-existing, potentially
lethal, metastatic deposits. This paradox is well illustrated by Posadas et al. 2016,
which explicitly attempted to examine the anti-metastatic effects of AZD0530 in men
who already had metastatic prostate cancer. The trial was to proceed with
randomization to either AZD0530 or placebo for patients that exhibited stable disease
following an initial lead-in period. The study was terminated after the majority of
patients progressed prior to randomization, preventing effective evaluation of antiinvasive or anti-metastatic activity101. Examining the anti-invasive effects of AZD0530,
dasatinib, or bosutinib requires treatment of early-stage patients, where pre-existing
micro-metastases are less likely to serve as a confounding variable and life-threatening
outgrowth of macro-metastases is not a factor.
The unusual clinical parameters of bladder cancer present a unique situation in
which anti-invasive activity is both measurable and of tangible benefit to patients.
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Among those with high risk NMIBC, the most immediate concern is not expansion of
lethal metastatic disease, but local invasion that presages systemic spread,
necessitating much more aggressive treatment. Anti-invasive agents, like SFK
inhibitors, present an alternative to highly invasive surgery and the possibility of leading
a much more normal life. To my knowledge, there has been one clinical trial examining
SFK inhibitors in bladder cancer patients. Hahn et al. 2016 employed a novel study
design, which involved neoadjuvant treatment with dasatinib in non-metastatic MIBC
patients, followed by cystectomy with curative intent. This model allowed for
examination of tolerability alongside molecular changes caused by dasatinib. Like
previous studies of SFK inhibitors, this trial was not intended to test anti-invasive
capacity. Patients included were of higher stage (MIBC, pT2 and above) than those
likely to benefit from such a strategy (NMIBC, pTa-pT1). In line with previous studies,
Hahn et al. 2016 saw minimal changes in proliferation or apoptosis, as measured by
Ki67 and cleaved caspase-3 staining of cystectomy samples102. However, dasatinib
was well tolerated in bladder cancer patients102, demonstrating that it would be possible
to test the SFK anti-invasion hypothesis in an appropriately designed trial. Should
preclinical studies support the effectiveness of SFK inhibitors in either unselected or
molecularly defined populations of NMIBC patients, clinical trials of these agents would
be warranted.
Src and Bladder Cancer Metastasis- Conflicting Observations
A great deal of evidence ties Src to the fundamental mechanics of cell motility,
as well as specifically to tumor invasion and metastasis. However, the picture in
bladder cancer is less clear. Recent studies by the Theodorescu group suggest that,
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rather than driving metastasis as is canonically accepted in other tumor types, Src
serves as a bladder cancer metastasis suppressor13,14. Their observations stand in
stark contrast to the field as a whole and raise important questions about the nature of
Src in this setting. While SFK inhibitors appear attractive as anti-invasive agents, there
is a risk that these therapeutics could have the opposite effect, driving progression in
patients rather than disrupting it. Before SFK inhibition can be considered for use in a
clinical setting, the exact role of Src in bladder cancer motility must be elucidated.
The first evidence that Src may antagonize invasion in bladder cancer came
from Wu et al. 2009, which examined Src through the context of interactions with a
known metastasis suppressor, RhoGDI2. RhoGDI2 is thought to decrease cell motility
through inhibition of Rho GTPases and guanine nucleotide exchange factors (GEFs).
Wu et al. identified Src as a novel binding partner of RhoGDI2. Using publicly available
datasets and a tissue microarray, they also found that, like RhoGDI2, Src expression in
bladder cancer decreased as a function of tumor stage, suggesting that loss of Src is
an important step in progression towards invasive, metastatic disease 13. These results
are in line with an early study which found higher Src expression associated with lowergrade bladder tumors, and enrichment of Src in RT4 cells, which are derived from a
low-stage tumor103.
Using site-directed mutagenesis experiments, Wu et al. 2009 concluded that Src
phosphorylates RhoGDI2 primarily at Y153. Phospho-mimetic Y153E RhoGDI2
exhibited altered activity relative to wildtype RhoGDI2, including increased membrane
targeting and decreased binding to RhoGTPase, Rac1. Transfection of UMUC3 bladder
cancer cells with wildtype or Y153E RhoGDI2 had minimal effects on in vitro
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proliferation, colony formation, and subcutaneous tumor growth. The impact on
metastasis however, was pronounced. Unsurprisingly, given its established role as a
metastasis suppressor, overexpression of wildtype RhoGDI2 in UMUC3 significantly
blunted experimental lung metastasis. Overexpression of Src phospho-site-mimetic
Y153E RhoGDI2 had even stronger effects on lung colonization, reducing metastasis to
less than 10% of that observed in control UMUC313.
Examined in isolation, the conclusions of Wu et al. 2009 are easy to reconcile
with the canonical understanding of Src as a metastasis promoter. While the authors
clearly demonstrate that phosphorylation of RhoGDI2 at the Src target site decreased
the metastatic potential of bladder cancer cells, they did not directly measure the
impact of Src on dissemination. Src interacts with a variety of protein substrates and
participates in negative feedback signaling that antagonizes its own pro-motility
activity21. It is entirely possible that, while Src phosphorylation of RhoGDI2 inhibits
metastasis, the net effect of Src in bladder cancer cells is to promote migration and
invasion. The experiments performed in Wu et al. 2009 are not designed to test this
hypothesis, and leave open the possibility that Src drives metastasis in bladder cancer.
These critiques were effectively addressed in a follow-up paper from the same
group. Thomas et al. 2011 directly explored the role of Src in bladder cancer by
modulating Src signaling through a combination of pharmacological and genetic
means. Transfection of invasive UMUC3 cells with constitutively active Y527F Src
moderately decreased transwell migration and Matrigel invasion. Conversely,
knockdown of Src or treatment with PP2 increased transwell migration in otherwise
non-motile RT4 cells. In an experimental lung metastasis model, Y527F Src-transfected
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UMUC3 series cells exhibited significant decreases in visible lung nodules and micrometastases, as measured by the presence of human DNA in the mouse lung. Similar
results were obtained using the mouse bladder cancer MB49 model, which exhibited
significantly less lung metastasis from subcutaneous tumors, when transfected with
Y527F Src. The authors concluded that anti-invasive and anti-metastatic effects of Src
were mediated by inactivation of the RhoA/C and their target, ROCK14. Thomas et al.
2011 clearly demonstrated that, at least in certain models, the net effect of active Src is
to inhibit bladder cancer invasion and metastasis (fig 4).
Src and Bladder Cancer Metastasis- Reconciliation through Subtype Heterogeneity
The years following these studies have seen the emergence and widespread
acceptance of bladder cancer molecular subtypes (fig 1). This paradigm further
complicates attempts to understand the nature of Src’s relationship with bladder cancer
motility. As previously stated, basal and luminal bladder cancers display different
characteristic gene expression patterns. One of the rationales for viewing Src as a panbladder cancer metastasis suppressor originated from its enrichment in lower- stage,
less invasive tumors13,14. The existence of bladder cancer subtypes confounds this
analysis. Luminal tumors are also enriched in lower stage, less invasive bladder
cancers5–7. In an analysis that is agnostic to subtype, any mRNA that is upregulated in
luminal cancers will be associated with less invasive disease. Additionally, the primary
models used to study Src in Wu et al. 2009 and Thomas et al. 2011, UMUC3 and
MB49, are representative of basal disease6.
Differences in metastatic behavior among basal and luminal tumors suggest the
possibility that they employ molecularly distinct mechanisms during dissemination.
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Figure 4 A model of Src as a metastasis-suppressor in bladder cancer. Though little has
been done to examined Src in bladder cancer, recent studies suggest Src may act in a noncanonical, metastasis suppressing role in bladder tumor models. Two mechanisms of Src
mediated metastasis suppression have been proposed. The first is activation of the known
metastasis-suppressor RhoGDI2, and the second is through antagonizing of known metastasispromoter, Cav-1.
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Basal tumors may downregulate Src as part of their progression towards invasive and
metastatic disease, as suggested by the results of Wu et al. 2009 and Thomas et al.
2011. In this setting, evidence suggests Src acts in a non-canonical fashion, behaving
as a metastasis suppressor. Alternatively, in luminal tumors, Src may have a more
canonical role, driving invasion as has been described in other tumor types11,12,83,85.
This model would resolve an apparent discrepancy on Src and bladder cancers in the
literature. As noted above, one of the studies that cemented Src’s role in metastasis
was performed in the NBT-II rat bladder cancer model84. The results of that study
directly contradict the conclusions in Wu et al. 2009 and Thomas et al. 2011.
This hypothesis requires further investigation. Differences in Src expression in
patient samples of known subtype must be confirmed. Additionally, the subtype status
of NBT-II is unknown. Given the heterogeneity of bladder tumors, even within the basal
and luminal subtypes5,6, additional models with reliable subtype calls are needed to
confirm this dichotomy. In terms of patient samples, publicly-available gene expression
datasets containing large numbers of bladder tumors make studying subtype-specific
expression patterns in various cohorts possible. To enable preclinical modeling, our lab
has previously published subtype calls for a panel of human bladder cancer cell lines 6.
Using these models, I performed a more detailed examination of Src in bladder cancer.
EMT and Metastasis- Plasticity Over Selection
Another outstanding question is what role, if any, the developmental program
EMT plays in bladder cancer metastasis. For a time, the EMT-model of dissemination
had widespread acceptance as an imported mechanism by which carcinoma cells
spread, with evidence for EMT as a driver of metastasis coming from a variety of
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difference model systems67,68,104. But more recently, EMT’s relevance has been
questioned, with some suggesting EMT is unnecessary for cancer invasion and
metastasis105,106.
Central to the EMT hypothesis is plasticity, as it requires cells to undergo
extensive but reversible phenotypic changes during dissemination. By contrast, earlier
lines of lines of evidence supported the notion of metastasis as a highly selective
process, wherein only rare tumor cells that had the appropriate characteristics to
complete each step in the metastatic cascade were able to colonize secondary sites
(fig 5). Fidler 1975 found that serial passaging of B16 murine melanoma cells in vivo
yielded increasingly lung-metastatic variants, suggesting selection for more metastasiscompetent subclones from the parental cell population107. Fidler and Kripke 1977
confirmed that pre-existing cell populations, rather than adaptation to the lung
microenvironment, drove this phenomenon. They isolated subclones from parental B16
cells in vitro and observed vast heterogeneity in metastatic potential, including a subset
of highly metastatic variants108. Similar results were observed in models of murine
fibrosarcoma109 and human breast cancer110, suggesting that the observation is
generalizable to a variety of cancer types. Kang et al. 2003 found evidence that specific
gene expression programs drive seeding of rare, metastasis-competent cells to
different organs. They isolated a bone-metastatic variant of the human breast cancer
cell line MDA-MB-231, which displayed enrichment for expression of IL11, CTGF, and
CXCR4 relative to the parental cells and an adrenal gland metastasis-derived clone.
Overexpression of those genes and another, OPN, dramatically increased bone, but
not adrenal gland, metastasis in the parental MDA-MB-231 cells110. Furthermore, Minn
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Figure 5 The decathlon model of metastasis. Early research suggested that the metastatic
cascade selected for only a small proportion of tumor cells by requiring the capacity to engage
in a variety of processes, ranging from local invasion to proliferation in a foreign
microenvironment. This selection was likened to a decathlon, in which athletes must
demonstrate prowess in multiple events to be successful. In this model, the cells that will go on
to seed secondary tumors exhibit a metastatic phenotype while still in the primary tumor. They
are, however, exceedingly rare, with their prevalence being a rate limiting factor in metastatic
spread.
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et al. 2005 identified different gene expression signatures among MDA-MB-231 clones
with site-specific affinity for lung, bone, or adrenal gland metastasis, despite a shared
“poor prognosis” signature111. The model derived from these lines of evidence supports
a view of the metastatic cancer cell as a decathlon athlete, which over time
accumulated the phenotypic alterations necessary to complete each unique step in the
metastatic process112. Implicit in this paradigm is the idea of a stable, highly aggressive
clone.
However, more recent studies support an alternative model of metastatic spread
that relies heavily on the ability of cancer cells to undergo changes in differentiation
state, and centers around EMT. EMT is a developmental program through which nonmotile epithelial cells shift into a partially- or wholly-mesenchymal state, imbuing them
with the ability to migrate and invade adjacent tissues66. This process is associated
with downregulation of cell-cell junction proteins, including E-cadherin, claudins, and
connexins, as well as various microRNAs that maintain epithelial identity, most notably
members of the mir200 family and miR-205. Mesenchymal markers including Ncadherin and vimentin are upregulated. At the transcriptional level these changes are
driven by EMT-inducing transcription factors that include Snail (SNAI1), Slug (SNAI2),
Twist1, Twist2, Zeb1, and Zeb2. Following metastatic dissemination, EMT is thought to
be reversed by an analogous mesenchymal-to-epithelial transition (MET), which
restores properties that facilitate proliferative expansion66 (fig 6). EMT and MET have
long been known to play critical roles in morphogenesis, and successive rounds of
EMT and MET are required for fetal development. Prominent examples include
delamination of neural crest cells and cardiac valve formation113. In each case, cells
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Figure 6 Epithelial to mesenchymal transition involves a series of plastic phenotypes.
EMT is a process by which epithelial cells undergo a phenotypic shift into a more mesenchymal
state, resulting in increased motility. This change can be to an intermediate epithelialmesenchymal phenotype (partial EMT) or an entirely mesenchymal phenotype (full or complete
EMT). Cells can also convert back into an epithelial or partially epithelial phenotype through an
analogous MET.
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that undergo EMT relocate to predesignated sites. They then return to an epithelial
state via MET and proliferate, giving rise to various structures.
There are also examples of EMT and MET in normal adult physiology. During
the initial stages of epidermal wound healing, inflammatory immune cells flood the site
of injury to clear potentially infectious agents. They also release various growth factors
that induce EMT in keratinocytes at the wound edge113. However, rather than
undergoing a complete EMT, which involves total loss of cell-cell contacts, the
keratinocytes retain elements of epithelial differentiation, including cell-cell adhesion.
This “partial EMT” allows them to migrate collectively into the wound bed. After reestablishing a barrier between the stroma and the external environment, keratinocytes
revert to a wholly epithelial state via MET114.
Fundamental Mechanics of EMT
While originally described in the context of development and wound healing,
EMT has also been heavily implicated in tumor invasion and metastasis. Many of the
fundamental mechanics of tumor cell EMT were initially characterized in vitro using the
rat bladder carcinoma cell line, NBT-II. Though NBT-II displays a stereotypical epithelial
morphology under normal conditions, Boyer et al. 1989 found that culturing these cells
on collagen or treatment with serum could induced transition to a “fibroblastic” EMT
state, characterized by loss of epithelial morphology and adoption of a motile,
mesenchymal phenotype115. This shift was associated with relocalization of cell-cell
adhesion proteins away from the plasma membrane116, though expression levels of ecadherin remained unchanged117, suggesting a partial, rather than full, EMT.

38

Importantly, as is seen in the EMTs that occur during normal physiological processes,
these changes were reversible, with MET occurring once cells were returned to normal
culture conditions115. Exposure to specific growth factors, including acidic Fibroblast
Growth Factor (aFGF)118, Tumor Necrosis Factor Alpha (TNFalpha)119, or Hepatocyte
Growth Factor (HGF)120 drove EMT in this model. Induction was mediated by both
autocrine and paracrine growth factor signaling, whereby tumor cells released growth
factors that drove EMT both in themselves and in surrounding, non-secreting tumor
cells120–122. The EMT transcription factor, Slug (SNAI2), was found to be both essential
to growth factor-induced EMT and capable of driving EMT on its own when ectopically
expressed123. These foundational elements, reversibility, hybrid E/M states, induction
via autocrine or paracrine growth factor signaling, and the importance of EMTpromoting transcription factors, remain central to our overall understanding of EMT in
cancer.
EMT and Metastasis
While the majority of the early work on EMT was performed in in vitro, later
research established relevance in animal models of metastasis. The seminal work that
placed an EMT-driven model of metastasis into the mainstream was published by Yang
et al. 2004 and employed the 4T1 preclinical syngeneic breast cancer model67. They
were the first to study EMT using a spontaneous metastasis model, which involves
implantation of tumor cells into one tissue (preferably the orthotopic site) and
measuring metastasis to distant sites. In contrast, experimental metastasis models,
including intravenous and intra-cardiac injections, are based on inserting cells directly
into the circulation, thereby bypassing the initial stages in the metastatic cascade.
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Experimental metastasis may also overestimate metastatic potential109, making the
experimental metastasis models less rigorous. Yang et al. 2004 also implanted tumor
cells into the orthotopic site, which likely provides the most representative
measurement of metastatic potential123.
Using mRNA microarray analyses to compare gene expression among a panel
of isogenic cell lines, Yang et al. 2004 identified Twist as upregulated in the locally
invasive and metastatic models. Knockdown of Twist in the most aggressive cell line,
4T1, severely blunted spontaneous lung metastasis67. This work served as the
conceptual foundation for a “complete EMT” model of metastasis, in which epithelial
carcinoma cells adopt a fully mesenchymal phenotype and spread individually to
distant organs through the lymphatic and circulatory systems. After arriving at distant
sites, they revert to a fully-epithelial phenotype via MET and proliferate, forming
secondary tumors124(fig 7).
While Yang et al. 2004 and other initial studies focused on the motilityassociated characteristics of EMT, it was later discovered that EMT could also drive
secondary tumor formation by promoting a stem cell-like phenotype. Macro-metastatic
outgrowth is thought to be driven by cancer stem cells (CSCs), which, like normal stem
cells, exhibit expression of stemness markers and enhanced self-renewal capacity125.
EMT correlates with a CSC phenotype, and may actually promote a CSC state.
Mani et al. 2008 found that increased expression of EMT markers in neoplastic
and normal mammary epithelium stem cell enriched CD44+ populations. They also
demonstrated that ectopic expression of either Snail or Twist in bulk populations of
Her2/neu- transformed human mammary epithelial cells dramatically increased soft
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Figure 7 The complete EMT model of metastasis. Early research suggested that tumor cells
utilized a complete EMT during the metastatic cascade, losing all vestiges of epithelial identity
and migrating as single cells to distant organs. According to this model, tumor cells would
undergo MET upon arrival at a secondary site, allowing them to proliferate and give rise to
macro-metastases. Adapt from Yang et al. 2006 and use here with permission of publisher
(American Association of Cancer Research, license number 5012060838595)124.
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agar colony formation and tumorigenicity126. The nature of the relationship between
EMT and stemness is highly context-dependent. For example, Xi et al. 2015 found that
SNAI2/Slug drove stem-like properties in the normal mammary gland and that Slug
knockdown effectively abrogated gland reconstitution by mammary epithelial cells.
Alternatively, in models of breast cancer, SNAI1/Snail, but not Slug, was essential for
colony and tumor formation125. More recent work has identified differences in stemness
between partial and fully mesenchymal cell populations. Kroeger et al. 2019 found
strong enrichment for stem cell markers and tumor-forming capability in oncogenetransformed mammary epithelial cells (HMLERs) exhibiting a partial EMT state relative
to both epithelial and highly-mesenchymal cell populations. These different phenotypes
were associated with different EMT transcription factors. Partial EMT stem-like cells
were enriched for Snail protein expression, and ectopic expression of Snail could
induce partial EMT and increased stemness in epithelial HMLERs. Highly
mesenchymal HMLERs were characterized by nuclear localization of Zeb1, and ectopic
expression of Zeb1 severely compromised tumor-initiating capacity127. These studies
clearly demonstrated the ability of EMT to drive the increased tumorigenicity necessary
for metastatic spread, with partial EMT being associated with greater increases in
stemness than fully mesenchymal states.
Early critiques of the EMT hypothesis noted the difficulty in directly observing the
transient EMT state in vivo or in patient samples128. It was also noted that many of the
models used in the growing body of EMT literature were cell lines128 that might not
faithfully recapitulate critical components of the metastatic cascade as it occurs in
humans. Later works addressed these criticisms by employing carcinogen-induced
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mouse tumor models and genetically engineered mouse models (GEMMs) to explore
EMT in a more physiologically-relevant context. Tsai et al. 2012 developed a 7,12
dimethylbenz(a)anthracene carcinogen-induced squamous cell carcinoma model with
doxycycline- inducible expression of Twist1. Treatment of tumors with topical
doxycycline induced EMT at the primary tumor site while allowing disseminated cells to
undergo MET. Alternatively, systemic doxycycline treatment resulted in irreversible
EMT. Only reversible EMT mediated by local activation of Twist in the primary tumor,
resulted in increased lung macro-metastases68. A complementary study was performed
by Tran et al. 2014 in GEMMs of breast cancer. Using MMTV-neuNT mice with a
doxycycline- inducible SNAI1 transgene, they demonstrated that transient expression
of SNAI1 increased both lung macro-metastasis and prevalence of bone-disseminated
tumor cells (DTCs). However, while continuous SNAI1 induction modestly increased
DTC counts, it resulted in significantly fewer lung metastases. Additionally, inducible
knockout of SNAI1 in the PYMT GEMM significantly reduced both bone DTCs and lung
macro-metastases104. In both studies, only transient, reversible EMT increased macrometastasis, suggesting that EMT followed by MET is necessary for completion of the
metastatic cascade.
Evidence Contradicting EMT: Nuance and Reconciliation
However, two subsequent high-profile papers challenged the conclusion that
EMT is essential for metastasis and asserted that it may not be necessary or even
relevant to the metastatic cascade. In order to examine the role of EMT in pancreatic
cancer metastasis, Zheng et al. 2015 generated Twist1 and SNAI1 knockout models of
the KPC mouse. Neither Twist1 nor SNAI1 knockout decreased the frequency of
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metastasis to the lung or liver. Spleen invasion was also unaffected. Cell lines derived
from knockout and control tumors were injected intravenously to measure experimental
metastasis. Again, no differences in the frequency of metastasis was observed105.
Fischer et al. 2015 used a lineage tracing construct to detect the occurrence of EMT
through activation of the mesenchymal FSP1 promoter in the PYMT breast cancer
GEMM. They found that macro-metastases in the PYMT model did not arise from
tumor cells that had previously expressed FSP1, suggesting the absence of an EMT
MET106.
While these studies appeared to contradict previous work supporting the EMT
hypothesis, they could be reconciled with the larger body of literature through a more
nuanced understanding of the complex nature of cancer EMT. Aiello et al. 2017 noted
that areas of dedifferentiation reminiscent of EMT within the KPC Twist1 and SNAI1
knockout tumors of Zheng et al. 2015, suggesting that the loss of TWIST1 or SNAI1
was insufficient to disrupt EMT in the KPC model129. In line with this reasoning, Krebs
et al. 2017 found that genetic deletion of a different EMT transcription factor, Zeb1, was
sufficient to disrupt metastasis in KPC mice69. The requirements for EMT likely vary
between different cellular contexts, and there are many EMT-promoting transcription
factors, each of which is theoretically capable of driving components of the EMT
program. Loss of any individual EMT factor, or EMT factors that are not essential in a
given context, may not disrupt EMT. Rather than demonstrating that EMT was
dispensable for metastasis in KPC mice, the study by Zheng et al. 2015 demonstrate
that Twist1 and Snail are not required for metastasis in the KPC model.
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Ye et al. 2017 argued that FSP1, selected for its role in EMT in a renal fibrosis
model130, is a poor EMT marker in the PYMT tumor model, suggesting that an FSP1driven lineage reporter construct would fail to detect EMT in these tumors131. Again, the
nature of the EMT program in individual models needs to be carefully considered. The
use of markers like FSP1, which are present on highly mesenchymal cells like
fibroblasts, may not identify EMT and/or partial EMT states in carcinoma cells131. The
work by Tran et al. 2014 noted above showed that the EMT-transcription factor SNAI1
was involved in metastasis of the PYMT model104, suggesting that while FSP1-positive
cells do not give rise to metastases in the PYMT model, EMT is still involved in the
metastatic process.
Epithelial Characteristics and Metastasis: Partial vs Complete EMT
Current research still supports a role for EMT, but the Complete EMT model
described in Yang et al. 2006 (fig 7) has been severely undermined by evidence
demonstrating tumor cells metastasize as clusters rather than as single, highlymesenchymal cells. Cheung et al. 2016 implanted PYMT tumor-derived organoids
composed of green fluorescent protein (GFP)- and red fluorescent protein (RFP)expressing cells orthotopically into new murine hosts. The resulting spontaneous
metastases were composed of both GFP and RFP expressing cells, indicating seeding
by cell clusters rather than individual cells. Circulating tumor cells (CTCs) from these
mice were also found to exist as clusters and retained the cell-cell adhesions
characteristic of epithelial cells132. Additional work demonstrated that the cell-cell
junction protein, e-cadherin, was essential to metastasis. Padmanaban et al. 2019
found that cells derived from PYMT tumors with adeno-CRE mediated-CDH1 (e45

cadherin) deletion failed to give rise to spontaneous metastases when implanted
orthotopically, or experimental metastases following intravenous injection. Identical
results were obtained with C3(1)-Tag breast cancer GEMM-derived cells133. These
studies suggested that metastasis resulted from cells with epithelial characteristics.
Loss of epithelial characteristics, rather than promoting metastatic spread, disrupted it.
Cheung et al. 2016 and Padmanaban et al. 2019 appear incompatible with a full
EMT model of metastasis, but they can be reconciled with an understanding of EMT
that incorporates hybrid epithelial-mesenchymal states, referred to as partial EMT (fig
8). As is the case in examples from normal physiology, EMT in cancer may involve a
complex series of intermediate states, with cells co-expressing epithelial and
mesenchymal markers and migrating collectively134. Importantly, studies of patient
samples support a partial EMT model. CTCs collected from patients with breast135,136,
lung137, and prostate135 cancer exhibit partial EMT, with expression of epithelial and
mesenchymal markers. They were also commonly found as clusters, retaining the cellcell adhesion characteristics of epithelial cells, with the mesenchymal migratory
capacity to spread from a primary tumor into circulation135–137. Cumulatively, the
available evidence suggests that EMT is a driver of invasion and metastasis, but plays
a more complex role than early preclinical studies implied. The study of EMT requires
examination of multiple different markers and an appreciation for the nuances of the
model used, as the characteristics EMT likely vary from system-to-system. Moreover,
markers of a complete EMT, like FSP1, may be poor readouts of the EMT programs
used by carcinomas. Though additional studies in both the preclinical and clinical
spaces are needed to further elucidate how specific tumors engage the EMT machinery
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Figure 8 The partial EMT model of metastasis. More recent research that integrates both
preclinical models and studies of patient samples suggests partial, rather than complete, EMT
drives metastasis. In this model, tumor cells adopt a partially mesenchymal phenotype while
retaining epithelial traits like cell-cell adhesion. Tumor cells then migrated collectively to
secondary sites. This model is supported by evidence demonstrating epithelial and
mesenchymal features promote metastatic spread, and the existence of partial EMT tumor cell
clusters in the blood of cancer patients. Adapt from Yang et al. 2006 and use here with
permission of publisher (American Association of Cancer Research, license number
5012060838595)124.
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and the nature that various EMT drivers play in different settings, current data still
support the importance of EMT in cancer metastasis.
EMT and Bladder Cancer
Early evidence for the role of EMT in bladder cancer metastasis came from
clinical studies. Slaton et al. 2004 found high expression of EMT-associated
matrixmetalloprotease-9 (MMP-9) and low e-cadherin expression (ratio of MMP-9 to ecadherin) was associated with decreased cancer-specific survival, a surrogate for
aggressive metastatic disease136. The same results were obtained in a study of upper
tract urothelial carcinoma138. These studies occurred prior to large scale micro-array
and RNA-sequencing efforts that identified distinct basal and luminal bladder cancer
subtypes4–6. Further subclassifications identified by characteristic gene expression, or
infiltrating stromal cell populations are also possible5,6. Differences in EMT marker
expression are evident among the different subtypes of bladder cancer. Expression of
EMT-related genes and a baseline partial EMT signature correlate with disease
subsets that are more likely to be both locally-invasive and metastatic. The association
between EMT and clinical aggressiveness suggests that EMT contributes to the
progression of bladder cancers.
Basal Bladder Cancer and EMT
Basal bladder tumors exhibit predominately epithelial morphology but coexpress epithelial and mesenchymal markers4–6, suggesting a partial EMT state.
Additionally, a fraction of basal cancers is further enriched with EMT and claudin-low
gene expression signatures4,137, in line with the association between EMT and
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aggressive clinical behavior, basal bladder cancers are nearly all muscle-invasive at
presentation7. Basal tumors are also more likely than luminal tumors to be metastatic at
presentation5 and patients with basal tumors have shorter overall4 and disease
specific5 survival.
Paradoxically, lymph node metastases from basal primary tumors displayed a
high propensity for basal-to-luminal subtype switching, and these shifts were
associated with intra-tumoral basal-luminal heterogeneity, as assessed by
immunohistochemistry (IHC)139. It is possible, given the apparent plasticity of these
primary tumors, that the luminal metastases were seeded by phenotypically basal cells
that shifted subtypes in response to the lymph node micro-environment. Alternatively,
they may have originated from luminal marker-positive cells, defying the existing
dogma linking basal bladder cancers to lethal metastatic disease. Another possibility is
that the mechanics of spread to distant organs and lymph nodes differ, with the latter
enriching for luminal cancer cells. Given the more severe clinical implications of distant
metastases, subtype concordance between those secondary tumors and matched
primaries may be more informative from both patient care and biological perspectives.
Gene expression analyses of basal tumors indicated activation of the master
transcriptional regulator, ΔNp63, a splice variant of p635. The co-activation of ΔNp63
and a partial EMT program is somewhat surprising, as ΔNp63 can antagonize certain
mesenchymal transcription programs, and is implicated in maintenance of an epithelial
phenotype140. In bladder cancer, ΔNp63α drives expression of the anti-EMT microRNA,
miR205, which represses expression of the EMT transcription factors Zeb1 and
Zeb2140. However, recent studies have demonstrated the ability of ΔNp63 to inhibit
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certain EMT transcription factors while at the same time promoting others. Work in
models of basal breast cancer have shown that ΔNp63α drives a hybrid epithelialmesenchymal phenotype by promoting expression of Slug141. Data in bladder cancer
models are consistent with these findings. While ΔNp63α knockdown increased Zeb1
and Zeb2 expression in the bladder cancer cell line UMUC6, it also decreased
expression of Slug. Ectopic expression of ΔNp63α increased Slug expression in highlymesenchymal UMUC3 cells140. Rather than occurring in spite of ΔNp63, the partial
EMT observed in basal bladder cancers may be part of ΔNp63’s activity.
Beyond increased invasive capacity, partial EMT may drive the aggressive
behavior of basal bladder tumors by promoting the tumorigenicity of disseminated
cancer cells. Stem cell marker- associated gene expression, which is enriched in basal
tumors alongside EMT markers4,5, is a predictor of poor outcomes in a variety of cancer
types142. While ectopic expression of ΔNp63α decreased in vitro measures of invasion
in bladder cancer, ostensibly through suppression of Zeb1/2140, the partial EMT state
driven by ΔNp63 may promote other stages of the metastatic cascade, including
outgrowth of secondary tumors. Hybrid epithelial-mesenchymal states are associated
with higher expression of stem cell markers and increased tumor- forming capacity127.
A partial EMT, driven by the activities of ΔNp63, may balance motility with
tumorigenicity, leading to increased metastatic efficiency.
While most bladder tumors display predominately-epithelial gross morphology,
rare, sarcomatoid bladder cancers exhibit spindle-like morphology reminiscent of
mesenchymal cells143. These cancers share a common lineage with basal tumors144
and can co-occur with traditional urothelial carcinoma143,145. They are extremely
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aggressive, with a high propensity to metastasize145 and are associated with very poor
patient outcomes143. Multiple studies have identified high EMT marker expression in
sarcomatoid tumors144,145, with aberrant activation of the EMT program hypothesized to
drive progression144. In spite of evidence that partial EMT promotes a more metastatic
phenotype, fully mesenchymal sarcomatoid tumors have worse patient outcomes than
those that co-express mesenchymal and epithelial-basal markers144. This apparent
contradiction may be linked to the established association between EMT and
chemoresistance. Patient mortality is only a surrogate for metastasis, which also
incorporates the responsiveness of tumors to systemic therapies. Multiple studies have
demonstrated that EMT and EMT transcription factors drive resistance to
chemotherapeutics105,106,146. The increased aggressiveness of fully mesenchymal
sarcomatoid tumors may stem from this phenomenon, though clinical and mechanistic
studies are needed to test this hypothesis.
Luminal Bladder Cancer and EMT
Luminal bladder tumors make up the vast majority of NMIBCs7, as well as
approximately half of MIBCs4. Overall expression of EMT markers is lower in luminal
relative to basal tumors4,5. Nonetheless, EMT marker expression correlates with
invasive behavior in these cancers as well. In a study of NMIBC, Hedegaard et al. 2016
found that progression to muscle invasion was more prevalent in the subset of tumors
enriched for EMT markers. Additionally, tumors that progressed to MIBC that originally
clustered separately from the EMT-enriched subset tended to adopt gene expression
associated with the EMT-enriched tumors following progression147. This correlation
suggests that EMT drives local invasion, even among luminal tumors that express
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lower levels of EMT markers in bulk tissue samples. The fact that luminal tumors are
less likely to be invasive may be due to a lower propensity for EMT. Alternatively, they
may employ different, less efficient mechanisms of invasion in lieu of the EMT program.
While progression is less common among the EMT-low NMIBCs, these cancers appear
to share a common lineage with a subset of muscle invasive luminal tumors6.
Among the muscle-invasive luminal tumors there are two major subclasses,
luminal papillary tumors and luminal infiltrated or p53-like tumors. These two subsets
also display differences in EMT marker expression, which again correlated with clinical
aggressiveness. Luminal papillary tumors express very low levels of EMT-associated
genes and high levels of claudin cell-cell junction proteins6. They are also the least
aggressive of the muscle invasive tumors. In the 2017 The Cancer Genome Atlas
(TCGA) analysis of MIBC, luminal papillary tumors presented at lower, less invasive
disease stage than any other subset, including other luminal tumors6.
Luminal infiltrated or p53-like MIBCs exhibit higher levels of EMT markers than
luminal papillary tumors, with mRNA expression comparable to that seen in basal
bladder cancer6. However, it is not clear that the EMT marker expression observed in
luminal-infiltrated tumors originates from the cancer cells. Luminal-infiltrated tumors, as
the name suggests, are characterized by a high degree of stromal cell infiltration,
particularly mesenchymal marker-positive fibroblasts5,6,148. Fibroblasts, rather than the
tumor cells, may be the source of EMT marker gene expression observed in these
patient samples. Fibroblasts could also drive the EMT marker positivity observed in
more aggressive NMIBC147, with the tumor cells retaining a fully epithelial phenotype
Based on the results of immunohistochemistry (IHC) studies, Sjodahl et al. 2017
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suggested that, outside of a subset of mesenchymal marker-enriched basal tumors,
bladder cancer EMT marker expression measured at the mRNA level originates from
stromal cell infiltration149. This interpretation is bolstered by the fact that luminal
infiltrated tumors express high levels of claudins and other cell-cell junction associated
genes, which are markers of epithelial identity6.
Alternatively, fibroblasts may induce partial EMT that would be difficult to detect
by IHC in the cancer cells of these tumors. In the bladder cancer cell lines 5637, T24,
and J82, treatment with conditioned media from cancer-associated fibroblasts (CAFs)
increased EMT marker expression and yielded increased invasion in vitro150. These
interactions can be reciprocal, with cancer cells secreting soluble factors that drive the
EMT-promoting activities of fibroblasts. Treatment of fibroblasts with exosomes derived
from RT4 bladder cancer cells induced release of fibroblast interleukin-6 (IL6), which in
turn induced EMT in RT4151. Wang et al. 2007 found that cancer cell conditioned media
enhanced fibroblast production of the known EMT-inducer, HGF, which increased
Matrigel invasion of 5637 bladder cancer cells, though changes in EMT markers were
not examined152. If it is the case that luminal infiltrated cancer cells exist in a partial
EMT state, fibroblasts may be part of what drives that phenotype.
While EMT-inducing fibroblast paracrine signaling is well documented,
alternative, EMT-independent mechanisms of fibroblast-driven cancer invasion also
exist. Gaggioli et al. 2007 found that in tumor sphere invasion models, CAFs served as
leader cells to invading strands of epithelial tumor cells153. These leader-follower
interactions were mediated by heterotypic N-cadherin/ E-cadherin junctions154, and
provide a model of fibroblast-induced invasion that is ostensibly unrelated to EMT. It is
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also possible that both paracrine-induced EMT and CAF leader cell-driven invasion
could occur simultaneously. Neither hypothesis has been thoroughly explored in
bladder cancer.
Studies of EMT in Preclinical Models of Bladder Cancer- A Bias Towards Basal
The study of EMT in bladder cancer preclinical models has been severely
hampered by the limited metastatic capacity of current model systems. Though many
human bladder cancer cell lines are widely available6,155, few if any of them readily
metastasize following orthotopic implantation. One solution to this problem was
identified by Dinney et al. 1995. Using tumor recycling, whereby orthotopically injected
cells are harvested from the mouse bladder and re-implanted in a new host following a
short time in culture, they generated a metastatic variant of 253J bladder cancer
cells156. Roth et al. 2017 employed this method to study metastasis in a panel of
bladder cancer cell lines. Of the five cell lines examined (UMUC3, UMUC6, UMUC9,
UMUC13, and UMUC14) only the two most mesenchymal cell lines (UMUC3 and
UMUC13) became reliably metastatic. Their study also found evidence supporting an
EMT-MET paradigm. Following orthotopic recycling, primary tumors derived from the
highly mesenchymal UM-UC3 and UM-UC13 cells displayed upregulation of Ecadherin, consistent with MET. Subsequent down-regulation of the epithelial marker
CDH1 (E-cadherin) and upregulation of the mesenchymal marker SNAI1 (Snail) were
evident in CTCs relative to their corresponding primary tumors or metastases.
Furthermore, inducible knockdown of SNAI1 substantially reduced CTC levels and the
emergence of metastatic lesions. Re-expression of SNAI1 reversed this phenotype157.
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While this study suggests that EMT is important to bladder cancer metastasis, it
does have some inherent limitations. The cell lines that metastasized and depended on
Snail to spread (UMUC3 and UMUC13) likely recapitulate the biology of basal bladder
cancers6 and therefore the results of Roth et al. 2017 may not be generalizable to
luminal tumors. There are also the caveats associated with all xenograft models.
Human cells that have been cultured on plastic for extended periods may fail to
faithfully recapitulate the complex, multi-step process of metastasis when implanted in
murine hosts. These concerns could be addressed by GEMM or carcinogen-induced
models of bladder cancer. However, there are limited options for studying bladder
cancer metastasis in the GEMM and carcinogen-induced space.
Liang et al. 2016 approached this problem using the established N-butyl-N-(4hydroxybutyl)nitrosamine (BBN)-carcinogen induced model. BBN exposure through
drinking water produces basal bladder tumors158,159, which, while minimally metastatic,
do reliably progress to muscle invasive disease160. They found that inducible knockout
of TGFB2R, which mediates the EMT-promoting effects of TGFB1, blunted the
emergence of muscle-invasive tumors161. This result, alongside the findings of Roth et
al. 2017, suggests that, at least in basal bladder cancer, EMT promotes tumor
progression. This conclusion is bolstered by a correlative study of the basal bladder
cancer cell lines, T24 and 5367. A metastasis-competent subclone of T24, known as
T24L, displayed higher expression of various EMT markers than parental cells 162.
Ectopic expression of androgen receptor in 5637 cells promoted both EMT and lymph
node metastasis, but a mechanistic link between these phenomena was not
established163.
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Other studies have employed tail-vein injection-mediated experimental
metastasis models or in vitro invasion assays to study EMT in bladder cancer. Data
generated with these techniques, while not representative of all steps in the metastatic
cascade, also support an EMT-driven model of metastasis. Knockdown of the EMTdriving lncRNA, malat1, decreased experimental metastasis of T24 cells164, suggesting
that EMT promotes survival in circulation or outgrowth at secondary sites. Ectopic
expression of Slug increased transwell invasion of 5637 cells, while Slug knockdown
decreased invasion in T24162. Similarly, siRNA against Zeb1 decreased migration of
both UMUC3 and J82 cells165. These studies should not be considered definitive in lieu
of research using more applicable orthotopic, GEMM, or carcinogen-induced models of
spontaneous metastasis. Increased in vitro invasive capacity does not always correlate
with increased metastatic potential, especially when it comes at the expense of other
metastasis-promoting characteristics, like stemness or cell survival. However, taken as
part of the larger context of the EMT literature in bladder cancer, and cancer more
broadly, these studies do serve to support some role for EMT in bladder cancer
metastasis.
As is the case with mouse model studies, the majority of data on EMT in bladder
cancer in vitro comes from cell lines that can be classified as basal6. Additionally, there
is heavy reliance on highly mesenchymal models, such as UMUC3 and T24. While
higher levels of in vitro motility make basal-mesenchymal lines a more practical choice
for studies of invasion, these cells may not be representative of luminal or basalepithelial biology. In order to understand whether EMT-mediated invasion is a general
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phenomenon in bladder cancer, or something restricted to a subset of tumors, more
expansive studies are needed.
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CHAPTER 2
MATERIALS AND METHODS
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Transwell Migration and Invasion Assays
Subconfluent cells were trypsinized, resuspended in serum containing media,
centrifuged, washed with PBS, centrifuged, and resupsended in serum free media.
30,000 to 60,000 cells were then seeded into the upper chamber of the transwell in
0.5ml of serum free media. The lower chamber was loaded with 30% fetal bovine
serum containing media to establish a chemo-attractant gradient. Migration or invasion
was allowed to proceed for 4 to 20 hours. Membranes were then fixed, uninvaded cells
wiped away, and remaining cells stained with gentian violet. The entire filter was
imaged by light microscopy and all invasion was quantified by counting invaded cells
using Fiji166. 8µm pore Matrigel coated transwells (354480) and uncoated transwells
(354578) were purchased from Corning. Collagen-1 coated transwells were generated
by applying 0.2mg/ml collagen-1 (Corning-354236) in PBS to uncoated transwell filters
overnight. Collagen-1 filters were rinsed with PBS and used immediately or stored at 4
degrees Celsius for up to one week.
Western Blotting
Subconfluent cells were harvested in RIPA buffer containing protease (Complete
Mini- 11836153001) and phosphatase(PhosSTOP-04906837001) inhibitors purchased
from Roche. Following protein quantification by BCA assay, samples were diluted and
boiled in 2x 2-Mercaptoethanol containing Laemmli sample buffer. SDS-PAGE gel
electrophoresis was run at 100 volts for 1.5 hours in Tris-Glycine-SDS buffer, followed
by transfer onto nitrocellulose membrane in Tris-Glycine buffer 20% methanol overnight
at 30 volts. Membranes were cut into strips by molecular weight and blocked in 5% milk
PBS for 1 hour. Membranes were incubated for 2 hours or overnight in primary
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antibody (1:1000 or 1:5000 dilution, 1% milk PBS), washed in PBS-T (PBS 0.1%
Tween 20), and incubated in secondary antibody for 1 hour (1:5000 dilution, 1% milk
PBS). In instances where multiple proteins of similar molecular weight were probed,
identical but separate blot were performed at the same time. Loading control (Actin)
was examined on previously probed blots. Primary antibodies were purchased from
Cell Signaling (Src polyclonal-2108, Src Monoclonal-2123, pY416 Src-6943, p130CAS13846, pY410 p130CAS- 4011, Smad2- 3122, pS465/468 Smad2-3108), ThermoFisher
(FAK- AHO0502, pY861 FAK- 44-626G) or Sigma-Aldrich (Actin- A2066). Goat antiRabbit secondary antibody was purchased from Biorad(1706515) and Rabbit antiMouse secondary antibody was purchased from Invitrogen(61-6520).
Chemicals and Reagents
AZD0530(S1006) and bosutinib(S1014) were purchased from Selleckchem.
Galunisertib was purchased from MedChemExpress (HY-13226). All inhibitors were
diluted to 10mM in DMSO and stored at -80 degrees Celsius. Prior to use, each was
diluted in media yielding at maximum a DMSO concentration of 0.1%.
Cells Culture
All parental cell lines were obtained from the Pathology Core of the Bladder
Cancer SPORE at MD Anderson Cancer Center, with the exceptions of T24 and
SCABER, which were purchased from the American Type Culture Collection. Cells
were cultured as monolayers with Minuimum Essential Medium containing 10% fetal
bovine serum (FBS), 1% nonessential amino acids, 1% vitamin solution, 1% PenicillinStreptomycin solution, and 1% sodium pyruvate. Incubator conditions were maintained
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at 37 degrees Celsius with humidified, 5% carbon dioxide atmosphere. Cell line identity
was confirmed by DNA fingerprinting through the MD Anderson Characterized Cell Line
Core and the Johns Hopkins School of Medicine Genetic Resources Core Facility.
Cell Line Spheroid Generation and Culture
Subconfluent cells were trypsinized and plated into ultra-low attachment, round
bottom 96 well plates (Corning- CLS7007) for 72 hours to form self-adherent spheroids.
Spheroids were then embedded in Matrigel domes (Corning- Matrigel GFR Membrane
Matrix-354230) submerged in culture media on a 24-well plate. Images of select
spheroids were taken immediately post-plating, with follow up images of the same
spheroids taken at 96 hours post-plating.
Proliferation Assay
Cells were plated at between 250 and 1500 per well in a 96 well plate and
allowed to adhere overnight. Drug containing media was applied at 24hrs and
refreshed at 72hrs. Drug media was replaced at 120hrs with media containing 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Following formation of
formazan, media was replaced with DMSO and absorbance at 570nm and 630nm was
taken using a spectrophotometer. Inhibitory concentration 50% (IC50) values were
calculated for each cell line based on dose response.
Immunofluorescence Staining and Attachment Assay
For immunofluorescence detection of vinculin, cells were plated onto chamber
slides in media containing AZD0530 or DMSO and allowed to adhere for 24 hours.
Cells were then fixed in 4% paraformaldehyde and stained with anti-vinculin primary
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antibody (Milipore Sigma- V9264), Donkey anti-Mouse Alexa Fluor 647 secondary
antibody (Invitrogen A-31571), and Rhodamine Phalloidin (Invitrogen- R415). Following
application of DAPI containing mounting medium (Invitrogen- ProLong Gold Antifade
Mountant with DAPI- D1306), representative images were taken at 20x using a
fluorescent microscope. For the attachment assay, cells were plated as described
above but onto standard tissue culture plates. Brightfield images were taken 24 hours
post plating and percentage of adherent cells was counted using Fiji166.
CRISPR-Cas9 Knockout Model Generation
UMUC6 cells underwent lentiviral transduction with doxycycline inducible Cas9
expression vector (Horizon Discovery-VCAS11227) and then underwent Blasticidin
antibiotic selection. Following doxycycline induction of Cas9, cells were transfected
using Lipofectamine RNAi Max (Thermo Fisher- 13778150) with Edit-R tracrRNA
(Horizon Discovery- U-002005-05) and either Src-targeting (Horizon
Discovery- CM003175-01) or Non-targeting (Horizon Discovery U-007501-01) crRNA
according to manufacturer protocol. Single cell clones were isolated and genomic DNA
was harvested using the Qiagen DNeasy Blood and Tissue Kit (69504). The region
surrounding the predicted DNA cut site was PCR amplified using custom primers
purchased from Sigma-Aldrich (forward primer- CCTGCTTTCGATGCCAACAG,
reverse primer- GACAGGTTGGGAGTGACCAT) with enzyme and master mix
purchased from New England Biolabs (Q5 Hot Start High-Fidelity 2x Master Mix
M0494L). PCR amplicons then underwent Sanger Sequencing at the Johns Hopkins
School of Medicine Genetic Resources Core Facility. Sanger Sequencing data was
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used for Tracking of Indels by DEcomposition (TIDE) analysis167 to identify clones with
predicted Src knockout. Loss of Src protein expression was confirmed by western blot.
RNA-Sequencing
To perform whole transcriptome RNA sequencing we used the Ion Torrent
AmpliseqRNA platform (Thermo Fisher). RNA was converted into cDNA using
SuperScript Vilo, which was in turn amplified with the Ion Ampliseq Transcriptome
human Gene Expression Core panel. Amplified cDNA underwent adaptor and barcode
ligation, and the resulting libraries were purified and quantified with the Ion Library
Quantification kit (Thermo Fisher, Inc). Purified libraries were diluted to a concentration
of 100pM, pooled in groups of 8, and amplified through emulsion PCR on Ion Sphere
particles, followed by enrichment with the IonChef (Thermo Fisher, Inc). Ion Sphere
particles containing template were loaded into Ion540 chips and sequenced on the
S5XL.
The AmpliSeqRNA analysis plugin from the Torrent Suite Software was used to
perform primary alignment analysis on the RNA sequencing data. Reads mapped per
gene was then used to produce a matrix of raw counts. A log-fold-change ranked list of
differentially expressed genes between DMSO and AZD0530 conditions was produced
using DESeq2168 (R ver. 4.0.3)169.
Publicly Available Patient Tumor and Cell Line Panel RNA Expression Data
Expression data from the TCGA patient cohort6 was downloaded from the Broad
Institute GDAC FireBrowse portal (http://gdac.broadinstitute.org/). The MDA patient
cohort data (GSE48075) and 30 bladder cancer cell line panel (GSE97768) datasets
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were downloaded from GEO (https://www.ncbi.nlm.nih.gov/geo/). Subtype calls of
luminal or basal were generated using a previous published gene expression
classifier170. In the case of the cell line panel, these calls were also previously
published6. Differential expression was measured by t-test using the Broad Institute
Morpheus software platform. Heat maps were also generated using Morpheus
(Morpheus, https://software.broadinstitute.org/morpheus).
Publicly Available Reverse Phase Protein Array Data
Reverse Phase Protein Array (RPPA) data for the TCGA cohort6 was
downloaded from the Broad Institute GDAC FireBrowse portal
(http://gdac.broadinstitute.org/). Subtype calls of luminal or basal based on RNA-Seq
profiling were applied to each tumor. Tumors that had not been sequenced and thus
lacked RNA based calls, four samples in total, were omitted from the analysis.
Differential expression of Src and pY416 Src was measured by t-test using the Broad
Institute Morpheus software. Heat maps were also generated using Morpheus
(Morpheus, https://software.broadinstitute.org/morpheus).
Data Analysis
Statistical tests for FGFR3 alteration enrichment (Fischer’s Exact test), baseline
Matrigel invasion (Mann-Whitney test), EMT marker (one-way ANOVA with Tukey’s
multiple comparisons test) and Src mRNA expression (Unpaired t-test), transwell
migration or invasion following drug treatment or genetic alteration (Ratio Paired t-test),
IC50(MTT Assay) and substrate attachment assay (Paired t-test) were performed using
GrapPad Prism 9.0.0 (GraphPad Software, Inc). Graphed data displays mean with
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standard error generated from biological replicates. In instances, such as prevalence of
FGFR3 alteration, where only a single value is appropriate, that value alone is graphed.
Cell line clades were created by hierarchical clustering using a Euclidian distance
matrix with average linkage on log2(x+1)-scaled RNA-Seq data (GSE97768).
Clustering was performed using the R Core Version 4.0.3169. Pathway analysis using
the Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, Inc) Upstream
Regulators Function was performed as previously described5. Additional statistical tests
performed by Morpheus and R software are discussed above.
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SRC IS UPREGULATED IN LUMINAL BLADDER CANCER
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Src as a Therapuetic Target in Bladder Cancer
Disease progression in bladder cancer is measured by degree of invasion into
the bladder wall. Lower stage, NMIBC (pTa-pT1) remains confined to the urothelium or
the lamina propria. NMIBC is treated with transurethral resection of bladder tumor
(TURBT) and intravesicular therapies, such as bacilli Calmette-Guerin (BCG)1. In these
patients, progression via tumor invasion into the bladder muscle wall is the greatest
clinical concern. The transition to MIBC is associated with further progression to lethal
metastatic disease, necessitating more aggressive treatment strategies. Standard-ofcare for MIBC is radical cystectomy with peri-operative, cisplatin-based chemotherapy.
Though justified by the risk of metastasis, this regimen is associated with high morbidity
and substantial reductions in patient quality of life1. Anti-invasive therapies may
improve outcomes for patients with high-risk NMIBC by disrupting disease progression
and thus delaying or preventing the need for more extreme measures, like cystectomy.
Src is a non-receptor tyrosine kinase that relays signals from transmembrane
receptor proteins, including growth factor receptors and integrins8. Through its
interactions with binding partner and kinase substrate FAK, Src regulates cell substrate
adhesion and cell migration9,10. Src has also been found to drive cancer cell motility
and metastasis in multiple tumor types11,12. Its established role in invasion and
metastasis, combined with the availability of clinical grade inhibitors, make Src an
attractive anti-invasive target. However, the role of Src in bladder cancer invasion and
metastasis is controversial. Several studies suggest Src actually inhibits invasion in
bladder cancer, both by activating metastasis suppressor, RhoGDI213and by
counteracting the activity of metastasis promoter, Cav-114. Given the ambiguity of the
67

relationship between Src and invasion in these tumors, and the potential clinical utility
of Src inhibition, further study of Src in bladder cancer is warranted.
Earlier examinations of Src took place prior to the advent of bladder cancer
subtyping. Bladder tumors can be divided into basal and luminal subtypes based on
expression of canonical urothelial differentiation markers4–6. These subsets have
different gene expression signatures and mutational patterns, making them related but
distinct disease entities. They also exhibit differences in invasion-associated gene
expression and behavior. Basal tumors are more likely to be metastatic at
presentation5, and display upregulation of EMT- associated genes4–6. Luminal tumors
are overrepresented among NMIBC7 and express high levels of claudin cell-cell
adhesion molecules6. However, luminal tumors also progress to muscle invasion and
metastasize4–6, possibly through different mechanisms than basal cancers.
The models in which Src has been shown to behave in a non-canonical,
metastasis-suppressing fashion are likely representative of basal disease. Src’s effect
on bladder cancer invasion may be mediated by intrinsic tumor subtype, with luminal
cancers sensitive to the anti-invasive effects of Src inhibition observed in other tumor
types. Additionally, NMIBCs, the subset most likely to benefit from anti-invasives, are
primarily luminal7. This situation presents an opportunity in which Src could be
exploited therapeutically in patients with outstanding clinical need.
Src is Upregulated in Luminal Clinical Samples in the MD Anderson Cohort
A previous study found that Src expression levels inversely correlate with
bladder cancer stage13. Based on this observation, Wu et al. 2009 argued that Src
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expression is lost as bladder tumors become increasingly invasive, suggesting that Src
suppresses invasion in bladder cancer. I sought to replicate those findings by
comparing Src mRNA expression among lower stage, NMIBCs, and higher stage,
MIBCs in the MD Anderson human bladder tumor cohort. In line with the results of Wu
et al. 2009, I found Src mRNA levels to be significantly enriched in NMIBCs (fig 9a).
While these data could be interpreted as supporting the Src-invasion suppressor
hypothesis, the existence of intrinsic bladder cancer subtypes, identified after the
publication of Wu et al. 2009, confounds this analysis. Different subtypes frequently
present as more (basal) or less (luminal) advanced disease, with luminal cancers
strongly enriched among NMIBC7. Therefore, any mRNA which is enriched in luminal
cancers will appear to be downregulated over the course of disease progression when
the subtype membership of tumors examined is not taken into account.
I decided to clarify the relationship between Src expression and disease
progression by comparing Src levels in luminal and basal bladder tumors in the MIBC
subset of the MD Anderson cohort. Using our previously published gene expression
classifier170, we subtyped these tumors as either luminal or basal. As expected, basalsubtyped tumors displayed enrichment for the basal urothelial differentiation markers
KRT5 and KRT14, while luminal subtyped tumors exhibited enrichment for luminal
urothelial differentiation markers KRT20 and GATA3 (fig 9b). Src mRNA expression
was significantly higher in luminal bladder cancers than in basal tumors as measured
by micro-array. These results suggest that, rather than being downregulated as a
function of stage, Src expression is enriched in luminal bladder cancers.
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Figure 9 Src mRNA expression is upregulated in luminal enriched NMIBC and luminal
subtyped MIBC in the MD Anderson Cohort. (A) Src expression is higher in lower stage,
NMIBCs, than in higher stage, MIBCs as measured by micro-array. (B) Within the MIBC subset
of the MD Anderson cohort, luminal-called tumors exhibit higher mRNA expression of Src than
basal-called tumors as measured by micro-array.
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Src is Upregulated in Luminal Clinical Samples in the TCGA Cohort
Having identified Src as being enriched in luminal cancers in the MD Anderson
cohort, I sought to validate this finding by examining Src expression in a separate
cohort of MIBCs. The TCGA cohort consists of over 400 MIBCs which underwent gene
expression profiling by RNA-Seq. Using the same gene expression classifier discussed
previously, these tumors were subtyped as either luminal or basal, and I compared Src
mRNA expression between the two groups. I found Src mRNA to be significantly
enriched among luminal bladder tumors relative to basal bladder tumors within the
cohort (fig 10a).
A portion of the TCGA cohort examined by RNA-Seq also underwent proteomics
analysis by RPPA6. I applied the mRNA-based subtype calls to the RPPA dataset, and
measured both expression of total Src protein and of Src autophosphorylation at Y416,
an indirect measurement of Src kinase activity. In line with the mRNA expression data,
luminal tumors exhibited enrichment for Src total protein (fig 10a). Src Y416 expression
was also enriched among luminal cancers, suggesting that Src activity is higher in
luminal tumors than their basal counter parts (fig 10b). These results are in line with
those obtained from the MD Anderson cohort, providing further evidence that Src is
enriched among luminal bladder tumors.
Src is Upregulated in Luminal Bladder Cancer Cell Lines
Having established that Src is enriched in luminal cancers across multiple
patient datasets, I examined Src expression in preclinical models of bladder cancer.
Bladder cancer cell lines can also be classified as luminal or basal, and our group has
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Figure 10 Src expression is enriched among luminal MIBCs in the TCGA cohort at both
the RNA and protein levels. (A) Src mRNA expression is enriched in luminal-called tumors in
the TCGA MIBC cohort as measured by RNA-Seq. (B) Src and Src pY416 protein expression is
enriched in luminal-called tumors in the TCGA MIBC cohort as measured by RPPA.

72

previously published subtype assignments for a panel of cell lines using the same gene
expression classifier we applied to the MD Anderson and TCGA cohorts6. Using
previously published RNA-Seq data6, I found that Src mRNA expression was
significantly enriched in cell lines that were called as luminal, relative to models that
were called as basal (fig 11a). I also measured Src protein expression in a subset of
the panel by western blot. Src protein levels correlated well with Src mRNA expression
in the cell lines (fig 11b). Cumulatively, these results demonstrate that Src is enriched
at the mRNA and protein levels in both luminal bladder cancer patient samples and
preclinical cell line models of bladder tumors.
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Figure 11 Src expression in enriched in luminal bladder cancer cell lines. (A) Src mRNA
expression is enriched in luminal-called bladder cancer cell lines as measured by RNA-Seq. (B)
Src protein expression correlates with mRNA expression in luminal-called bladder cancer cell
lines.

74

CHAPTER 4
AZD0530 INHIBITS MOTILITY IN LUMINAL BLADDER CANCER
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AZD0530 Inhibits Src Signaling In Bladder Cancer Cell Lines without Disrupting
Proliferation
Having established that Src is upregulated in luminal cancers, I decided to
examine the impact of Src inhibition in a subset of the cell line panel using the kinase
inhibitor, AZD0530. AZD0530 is an orally available, competitive, ATP-binding domain
inhibitor of Src and other SFKs87. It is well- tolerated in humans with a mild side-effect
profile96. AZD0530 reduced Src autophosphorylation, an indirect measurement of Src
kinase activity, in RT112 cells, with maximal inhibition occurring at dose of 1µM (Fig
12a). AZD0530 had minimal anti-proliferative activity as measured by 7 day 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) proliferation assay, with
IC50s for most cell lines well above the effective, Src inhibiting, dose (fig 12b).
Downstream signaling effects of AZD0530 were comparable in all models tested.
Treatment with 1uM AZD0530 abrogated phosphorylation of FAK Y861, a direct target
of Src, and p130CAS at Y410, a target of the Src-FAK signaling complex, in luminal
UMUC6 and RT112, as well as basal T24 and SCABER (fig 12c).
AZD0530 Inhibits Motility in Luminal Models
I next determined the effects of AZD0530 on bladder cancer motility using
transwells coated with various protein substrates. The bladder wall is composed of
multiple different layers, each of which is comprised of distinct sets of matrix proteins. A
basement membrane, which can be approximated in vitro by Matrigel171, separates the
urothelium from the underlying muscle wall172. The muscle wall itself is rich in collagen1173, a matrix protein known to promote invasive behavior174. In an effort to account for
the variability in matrix composition, I measured the impact of AZD0530 in transwells
76

A

B

C

77

Figure 12 AZD0530 has comparable anti-proliferative and anti-Src signaling effects on
luminal and basal models. (A) AZD0530 inhibits Src activity in a dose dependent manner with
maximal inhibition observed at 1µM. (B) AZD0530 has minimal anti-proliferative activity in
bladder cancer cell lines as measured by MTT assay. No subtype specific pattern in drug
sensitivity is observed. (C) 1µM AZD0530 inhibits Src signaling in luminal and basal models,
abrogating phosphorylation of Src targets FAK and p130CAS.
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coated in Matrigel (Matrigel invasion), collagen-1 (collagen invasion), and uncoated
transwells (migration).
The majority of luminal cell lines failed to invade Matrigel to any appreciable
degree, a result further explored elsewhere in this document. Among the luminal
models that did penetrate through Matrigel two lines, (UMUC6 and UMUC10) exhibited
significantly reduced invasion when treated with AZD0530 and one (UMUC9) displayed
mild, but statistically insignificant reductions in invasion. Only one of seven basal
models (UMUC3) was less invasive when treated, with another cell line (UMUC13)
actually invading Matrigel significantly more (fig 13a). AZD0530 caused significant
reductions in collagen invasion in all seven luminal cell lines tested, while only two
(UMUC3 and T24) of seven basal cell lines showed decreased invasion (fig 13b).
Again, the basal cell line, UMUC13 invaded significantly more rapidly through collagen1 coated transwells when treated with AZD0530 (fig 13b). Finally I sought to measure
the impact of AZD0530 on migration using uncoated transwells. Here, the differences
between basal and luminal models were the most striking. All luminal cell lines tested
migrated statistically significantly less following AZD0530 treatment (fig 13c). There
were no reductions in migration among the basal cell lines in our panel. Moreover,
greater than half of the basal models tested migrated faster when treated with
AZD0530 (fig 13c). These results suggest that while AZD0530 had similar effects on
Src-associated cell signaling in both subtypes, luminal models are substantially more
sensitive to the anti-invasive and anti-migratory effects of the inhibitor.
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Figure 13 AZD0530 inhibits motility in luminal bladder cancer models. Treatment with 1µM
AZD0530 inhibits luminal (A) Matrigel invasion, (B) Collagen—1 invasion, and (C) migration in
transwell assays. Basal motility is either unaffected or increased by AZD0530.
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AZD0530 Disrupts Substrate Attachment in Luminal Models
The differences in AZD0530’s anti-invasive activity between basal and luminal
models (fig 13) occurred in spite of similar cell signaling responses to the compound
(fig 12c). Given this apparent discrepancy, I sought to further characterize the
phenotypic effects of AZD0530 in sensitive luminal and resistant basal models. Src is
involved in regulating the turnover of FAs47, protein rich structures that anchor the actin
cytoskeleton to the ECM. FAs can be visualized by immunofluorescence staining for
the FA protein, vinculin, with vinculin puncta marker the location of FAs175. Vinculin
puncta, and therefore FAs, were reduced in luminal UMUC6 (fig 14a) and basal T24
(fig 14b) cells when plated in the presence of AZD0530. Despite this apparently similar
result, AZD0530- treated UMUC6 and T24 displayed radically different substrate
adhesion phenotypes. As is evident in fig 4a, in the presence of AZD0530, UMUC6 was
unable to attach to tissue culture plastic, displaying a rounded, non-adherent
phenotype. AZD0530-treated T24 cells, by contrast, were able to adhere to the tissue
culture surface (fig 14b).
I quantified this phenotype in luminal UMUC6 and RT112 cells. Exposure to
AZD0530 in plating media significantly reduced the fraction of attached cells in both
models (fig 14c). AZD0530 exposure had minimal effects on T24 and SCABER
substrate adhesion (fig 14c), with the majority of these cells still capable of attaching to
the culture surface. Surface adhesion is likely a prerequisite for transwell migration and
invasion. The failure of AZD0530-treated models to adhere to culture surfaces may
therefore underly the sensitivity of these cell lines to AZD0530 in transwell assays.
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Figure 14 AZD0530 disrupts substrate adhesion in luminal bladder cancer models.
Exposure to 1µM AZD0530 inhibits focal adhesion complex formation, as measured by Vinculin
staining in (A) luminal UMUC6 and (B) basal T24 cells. (C) Treatment only disrupts substrate
adherence in luminal models, with luminal UMUC6 and RT112 cells exhibiting impaired
attachment when exposed to 1µM AZD0530, while basal T24 and SCABER cells retained
adherence.
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Src Inhibition is Not Responsible for the Anti-Invasive Activity of AZD0530
In addition to Src and other members of the Src Family, AZD0530 inhibits other
tyrosine kinases with a high potency44. To establish the relevance of Src inhibition to
the AZD0530 phenotype, I generated Src knockout subclones of the AZD0530sensitive luminal cell line, UMUC6, using CRISPR Cas9. Subclones where screened by
Sanger Sequencing (data not shown) with the absence of Src protein confirmed by
western blot. Two clones, Src 54 and Src 65, were predicted to lack functional Src.
Western blotting with a polyclonal anti-Src antibody showed complete lack of Src under
normal exposure conditions (fig 15a). Overexposure of polyclonal blots showed mild
residual signal in both Src 54 and Src 65, raising the possibility of the presence of low
levels of functional Src protein.
As previously noted, there is a high degree of sequence homology among
members of the Src family, which raises the possibility of cross-reactivity of Src
antibodies with other SFKs. Manufacture information for the polyclonal Src antibody
notes low-level reactivity against other SFKs. To confirm that other SFKs, rather than
residual Src expression, was responsible for this phenomenon, I used a more specific,
monoclonal antibody to measure Src expression in Src 54 and Src 65. No signaling
was detected by the monoclonal Src antibody (fig 15a), confirming that Src had been
successfully knocked out in these subclones. Additionally, reductions in Y416 Src
(reduced but not eliminated, as the antibody cross reacts with other SFKs), and pY861
FAK demonstrate successful disruption of Src associated signaling in Src 54 and Src
65.
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After characterizing the cell signaling effects of knocking out Src, I measured the
impact of Src loss on motility using a transwell migration assay. In contrast to
expectations set by the AZD0530 Src inhibition phenotype, Src knockout clones
migrated significantly more than either NT clone tested (fig 15b). This outcome mirrored
the results of Wu 2009 and Thomas 2011, suggesting that Src suppresses, rather than
promotes, migration in bladder cancer cells.
Chronic loss of Src signaling in KO models may have different effects than acute
disruption achieved by chemical inhibition. Alternatively, off-target effects of AZD0530,
against other SFKs or any of the numerous kinases inhibited at high potency by the
compound44, could be responsible for the discrepancy between the AZD0530 and KO
results. To explore these possibilities, I treated NT and Src KO clones with AZD0530
and measured transwell migration. Despite the absence of Src, KO clones remained as
sensitive as NT cells to AZD0530, with both sets of cell lines exhibiting significant
reductions in migration following treatment (fig 15c). These changes were comparable
to those seen in parental cells (fig 13c) suggesting that the anti-migratory effects of
AZD0530 are mediated by inhibition of a target or targets other than Src.
AZD0530’s Inhibition of TGFBR1 does not Disrupt Migration
In an effort to identify possible alternative targets of AZD0530 in UMUC6, I treated
parental cells for 24hrs and harvested RNA for RNA-Seq analysis. Seeking an
unbiased approach, I used the Ingenuity Pathway Analysis (IPA) Upstream Regulators
function to explore broader patterns of mRNA expression in DMSO and drug-treated
conditions. This method uses global changes in gene expression to approximate the
relative activity of transcriptional regulators in different samples.
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Figure 15 Src KO increases migration in luminal UMUC6 cells. (A) CRISPR-Cas9 mediated
Src ablation phenocopies the cell signaling effects of AZD0530 with ablation of Src-associated
signaling. (B) Src KO clones exhibit increased migration relative to NT construct clones. (C) Src
KO and NT clones exhibit comparable sensitivity to 1µM AZD0530 treatment.
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Among the most significant changes induced by AZD0530 was a predicted
decrease in activity of the TGF-Beta signaling complex and downstream effector,
SMAD2 (fig 16a). As previously discussed, TGFBR1 is a common off-target of Src
inhibitors, including AZD053044. Given the established role of TGF-beta signaling in
motility74, this complex was a compelling candidate for AZD0530’s phenotypically
relevant target. I decided to explore this hypothesis by comparing co-inhibition of Src
and TGFBR1 with AZD0530 to the impact of inhibiting either target individually.
Bosutinib, like AZD0530, is a SFK inhibitor that inhibits Src and other family members
with high potency44,88. It has a different off-target profile than AZD0530, with no
predicted activity against the TGF-beta signaling complex44. Galunisertib is a kinase
inhibitor that targets TGFBR1176 but is not thought to inhibit SFKs44.
I validated the predicted target specificity of these compounds by western blot.
As expected, AZD0530 inhibited TGFBR1 signaling as measured by S465/467
phosphorylation of downstream substrate SMAD2 (fig 16b). Bosutinib inhibited Src
signaling comparably to AZD0530, but had no impact on SMAD2 phosphorylation (fig
5b). Galunisertib did not inhibit Src but did abrogate SMAD2 phosphorylation similarly
to AZD0530 (fig 17b). Combination treatment with bosutinib and galunisertib was
required to recapitulate the dual Src/TGFBR1 inhibition observed with AZD0530
treatment (fig 6b).
I then compared the ability of these agents to disrupt transwell migration in the
parental luminal models, UMUC6 and RT112. Bosutinib failed to inhibit migration in
parental UMUC6 (fig 16c), in line with the Src KO results (fig 15b). Unlike in the case of
the UMUC6 Src KO clones, bosutinib treatment inhibits all SFKs44. The failure of
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bosutinib to inhibit migration in UMUC6 therefore demonstrates that broader SFK
inhibition is not responsible for the anti-migratory effects of AZD0530. While
galunisertib did significantly inhibit UMUC6 migration, the effect was much smaller than
that observed with AZD0530, and the combination of bosutinib and galunisertib
decreased migration to a degree that trended toward, but did not reach statistical
significance (fig 16c).
RT112 cells did exhibit statistically significant decreases in migration when
treated with bosutinib, suggesting that, unlike UMUC6, they may rely on Src or other
SFKs for motility. However, the magnitude of the decrease was substantially less than
that seen with AZD0530 (fig 16d), suggesting again that other drug targets play a role
in the AZD0530 phenotype. Galunisertib failed to reduced migration in RT112, while the
combination of galunisertib and bosutinib decreased migration to a degree comparable
to bosutinib treatment alone (fig 16d).
An Exploration of Other Possible AZD0530 Targets
While TGFBR1 inhibition is unlikely a driver of AZD0530’s anti-motility effects,
the discrepancy in response between bosutinib and AZD0530 does present an
opportunity to identify other candidate targets. Klaeger et al. 2017 identified target
profiles for all clinical kinase inhibitors available at the time of publication using a cell
lysate-based platform known as kinobead. By leveraging the kinobead profiles of these
compounds, I identified punitive targets of AZD0530 that were not shared by bosutinib.
Using an apparent dissociation constant of 500nM as a cutoff I identified 5 candidates
in addition to previously examined TGFBR1 including ADCK3, ACVR1B, BMPR1A,
ACVR1, and RIPK2 (fig 17a).
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Figure 16 Inhibition of TGF-beta signaling does not drive AZD0530’s anti-migratory
activity. (A) AZD0530 treatment in luminal UMUC6 reduces predicted activation of the TGFbeta signaling axis as determined by IPA Upstream Regulator analysis. (B) AZD0530 inhibits
TGF-beta signaling similarly to TGFBR1 inhibitor, galunisertib, while structurally distinct SFK
inhibitor, bosutinib, does not. TGFBR1 inhibition alone or in conjunction with SFK inhibition fails
to replicate the AZD0530 antimigratory phenotype in luminal models (C) UMUC6 and (D)
RT112.
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I then examined mRNA expression of these candidates in the TCGA (fig 17b)
and MD Anderson (fig 17c) MIBC cohorts. Only one target, ADCK3, also known as
CABC1, was enriched among luminal tumors in both datasets. ADCK3 is a member of
the Ubi protein kinase-like family177 that is involved in synthesis of the mitochondrial
electron transport chain component, Coenzyme Q178. Though there is currently no
evidence from the literature specifically linking ADCK3 to tumor cell invasion, there is
extensive support for the notion of mitochondrial activity is as a driver of tumor
invasion179. However, ADCK3 was not enriched among luminal bladder cancer cell
lines, where sensitivity to AZD0530 is observed (fig 17d).
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Figure 17 Comparison of AZD0530 and bosutinib kinobead profiles

identifies ADCK3 as possible AZD0530 target. (A) AZD0530 inhibits several targets
unaffected by bosutinib, including ADCK3, TGFBR1, ACVR1B, BMPR1A, ACVR1, and RIPK2.
(B) Two possible AZD0530 targets, ADCK3 and ACVR1B, are enriched in luminal-called
tumors in the TCGA MIBC cohort, as measured by RNA-Seq. (C) One possible AZD0530
target, ADCK3, is enriched in luminal-called tumors in the MDA MIBC cohort as measured by
micro-array. (D) None of the possible AZD0530 targets are enriched in luminal called bladder
cancer cell lines.
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EMT IS ASSOCIATED WITH INVASIVE CAPACITY
IN BLADDER CANCER CELL LINES
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EMT and Luminal Cancers
While evidence from both patient samples and preclinical models suggests a
role for EMT in invasion and metastasis of basal bladder cancers, little is known about
EMT in luminal tumors. Determining the impact of EMT on invasion in bladder cancer
first requires the models used to be characterized, both in terms of subtype and EMT
status. Previously, our lab has published a PAM classifier, which designates bladder
tumors as either basal or luminal based on mRNA levels of a series of genes that
differentially expressed amongst the subtypes170. I first explored its ability to
distinguish between basal and luminal tumors in the TCGA MIBC dataset of over 400
human tumors. I examined expression of canonical basal markers, the epithelial
cytokeratins KRT14 and KRT5, as well as canonical luminal markers, the transcription
factors FOXA1 and GATA3. KRT14 and KRT5 were enriched among the basal-called
tumors, while both GATA3 and FOXA1 were enriched among luminal called-tumors (fig
19a). These results demonstrated that our classifier is able to effectively differentiate
between the main subtypes of bladder cancer in human tumors.
Basal and Luminal Called Cell Lines Fail to Fully Mimic Human Tumors
Our lab has previously published subtype calls using the classifier for a panel of
bladder cancer cell lines6. The posterior probabilities generated by the classifier
indicated high call confidence for 26 of 30 cell lines, with only four models (HT1197,
UMUC15, BV, and UMUC10) exhibiting call certainty below 70% (table 1). The majority
of calls had posterior probabilities of above 90%. This outcome suggests that, despite
being trained on patient samples, the classifier is able to assign subtype memberships
to preclinical models. To further validate the subtype calls, I examined the same luminal
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Table 1 Subtype classifier assigns calls to luminal and basal cell lines with high
confidence. A subtype classifier was applied to our panel of bladder cancer cell lines, calling
13 models as basal and 17 models as luminal. The majority of calls were made with high
confidence, with only four models have posterior probabilities below 70%. Analysis performed
by Dr. Andrea Ochoa and used here with her permission.
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(FOXA1, GATA3) and basal (KRT14, KRT5) markers used to test the classifier human
tumor assignments (fig 19b). In contrast to the clear dichotomies seen in the TCGA
dataset, FOXA1/GATA3 and KRT14/KRT5 expression did not neatly separate along
basal luminal lines. Among the basal cell lines 1A6, 5637, and SCABER exhibited the
expected expression pattern, with upregulation of KRT14/KRT5 and downregulation of
FOXA1/GATA3. The remaining basal-called models were negative for both sets of
markers.
KRT14 and KRT5 expression is restricted to the epithelium, with minimal
expression observed in cells of mesenchymal origin. Some cultured cancer cells exhibit
strong mesenchymal marker expression suggestive of a near complete EMT that would
include downregulation of epithelial genes. Such a phenomenon could explain the
absence of canonical basal marker expression in these models. I confirmed the EMT
status of these cell lines by examining expression of epithelial markers CDH1 (ecadherin) and Tp63 as well as mesenchymal markers ZEB1 and ZEB2 (fig 19c). Basal
models that lacked KRT14/KRT5 expression were ZEB1/ZEB2 high, CDH1/Tp63 low.
The reverse was true for KRT14/KRT5 positive basal models. Therefore, loss of
epithelial identity, rather than subtype miss-assignment, likely explains the lack of
KRT14 and KRT5 expression in this subset of basal-called models.
The enrichment of EMT marker expression is the basal cell lines is consistent
with the observations made in human tumors4,5, where mesenchymal gene expression
is a hallmark of basal tumors. However, patient tumors exhibit co-expression of
epithelial and mesenchymal markers4,5, indicative of a partial EMT, rather than the
complete EMT seen in the cell line models. While highly mesenchymal, sarcomatoid98
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Figure 18 Luminal and basal called models do not exhibit canonical marker expression.
(A) Tumors from the TCGA MIBC dataset exhibit canonical luminal and basal marker
expression in line with subtype assignment while (B) bladder cancer cell lines do not. This
discrepancy is due to expression of basal markers in many luminal-called lines and (C) EMTassociated loss of basal cytokeratin expression in basal-called lines.
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basal tumors do exist, they are rare143, and it is improbable that the majority of our
basal models are derived from such cancers. The adoption of a pronounced EMT is
more likely the result of extended ex vivo cell culture and appears to be feature
primarily restricted to basal-called cell lines.
A different discrepancy is apparent of the luminal subtyped models. The majority
of these cell lines exhibit co-expression of basal and luminal markers (fig 19c),
suggesting a mixed rather than purely luminal phenotype. Cell culture driven subtypeswitching has been documented in other systems. Lee et al. 2018 observed changes in
subtype marker expression in a series of patient derived organoid lines. The
differences were evident relative to both earlier in vitro passages and the clinical
sample from which the lines were established. The subtype transitions observed were
predominantly from luminal to basal180. Those findings are consistent with my own.
While luminal cell lines adopted expression of basal markers, limited expression of
luminal markers is observed in basal lines. Considering these results together, it is
likely that in vitro culture conditions promote a “basalification” of the cell lines, which
may complicate attempts to compare these models directly to patient tumors.
Unbiased Analysis Identifies Differences in EMT Status Among the Cell Line Panel
The cell line subtypes exhibit some characteristics of luminal and basal patient
tumors, including enrichment for EMT markers in basal models and enrichment for
FOXA1 and GATA3 in the luminal models. However, given the differences between
the human tumor and models, additional characterization is needed. To describe our
models in an unbiased manner, we employed hierarchical clustering based on global
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gene expression. The cell lines segregated into two large clades, with only the isogenic
cell lines 253JP and BV, and UMUC4 clustering outside of the main branches (fig 19a).
The clades largely broke down along EMT lines. The right-most cluster
consisted predominantly of the KRT14/KRT5 low ZEB1/ZEB2 high basal cell lines. Also
in this grouping was UMUC12, the lone luminal cell line that also exhibited a strong
EMT phenotype. Notably, the EMT marker negative basal models were excluded from
this cluster, suggesting that EMT status is a stronger driver of clade membership than
intrinsic subtype. I thus refer to this grouping as the mesenchymal cluster (fig 19a). The
larger, left most clade consists of both epithelial marker positive basal cell lines and the
majority of luminal cell lines, which were also epithelial marker positive. I thus refer to
this clade as the epithelial cluster (fig 19a).
A branch within the epithelial cluster exhibited statistically significant enrichment
for cell lines with known oncogenic alterations to the growth factor receptor, FGFR3 181–
183

(fig 19b). Activating mutations and translocations are a hallmark of the luminal

papillary subset of luminal bladder cancers6. Strong enrichment for these alterations,
and the association with luminal papillary tumors, raises the possibility that these
exhibit distinct properties from the rest of the epithelial cluster. I therefore designated
this group the luminal papillary subcluster (fig 19a).
In order to examine broad variation in gene expression amongst the main
clusters I employed Ingenuity Pathway Analysis (IPA) Upstream Regulators function.
This method uses global gene expression differences to infer the activation state of
various transcriptional regulators. These results largely recapitulated the patterns
suggested by EMT marker expression and subtype status. The mesenchymal cluster
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Figure 19 EMT status stratifies bladder cancer cell lines into two main groups
(A) Hierarchical clustering divides cell lines into large epithelial and mesenchymal clusters, (B)
with an FGFR3 alteration enriched luminal papillary subcluster within the epithelial cluster. (C)
IPA Upstream Regulator analysis demonstrates activation of EMT associated networks in the
mesenchymal cluster, with luminal and basal associated networks activated in the epithelial
cluster. Clustering dendrogram produced by Adam Aragaki and used here with his permission.
All downstream analyses stemming from this dendrogram are my own.
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exhibited expression patterns suggestive of activity of EMT promoting factors including
TGFB1, SNAI1, SNAI2, and ZEB1 (fig 19c). This result further emphasizes the
importance of EMT status in driving the co-segregation of these models and
demonstrates EMT as the main difference between mesenchymal and epithelial
clusters. Consistent with the mixture of subtype calls for the models it contains,
upstream regulators active in the epithelial cluster suggest a mixture of basal and
luminal phenotypes. Gene expression of models in this group indicated activity of the
estrogen receptor and PPARG, both known characteristics of luminal MIBC5. The basal
transcriptional regulators TP63 and NFkB5 were also active in this clade (fig 19d).
Luminal Papillary Subcluster Membership is a Better Predictor of Invasion that Binary
EMT-Status
Having established that complete EMT is one of the main factors that
differentiates bladder cancer cell lines from each other, I sought to examine invasion as
a function of EMT-status. I determined baseline invasion across the epithelial and
mesenchymal clusters using Matrigel-coated transwells. Matrigel has a composition
similar to basement membrane171, the barrier separating the urothelium from the
underlying muscle layer. Penetration of the basement membrane is a major clinical
milestone in bladder cancer progression, portending further local invasion as well as
wide spread dissemination. Matrigel invasion thus serves as an important in vitro proxy
of in vivo invasive potential.
Despite strong evidence implicating EMT in invasion, differences between the
epithelial and mesenchymal clades were statistically insignificant (fig 20a). Both
clusters contained highly and minimally invasive cell lines, with broad overlap between
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Figure 20 Luminal Papillary status, not binary EMT status, predicts invasion. (A) There is
not statistical difference in Matrigel transwell invasion between the epithelial and mesenchymal
clusters. However, (B) the majority of non-invasive cell lines reside in the luminal papillary
subcluster, (C) which does exhibit significantly decreased invasion.
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baseline capacity observed. These data suggest that when EMT is viewed as a binary
(cell lines classified as completely mesenchymal or completely epithelial), EMT is a
poor predictor of invasion in bladder cancer.
However, closer examination of the data revealed striking differences between
portions of the epithelial cluster. The least invasive models within the entire panel fell
almost exclusively within the luminal papillary subcluster (fig 20b). Nearly all of the
luminal papillary cell lines failed to invade Matrigel to any appreciable degree. Only one
model in the group, UMUC6, exhibited any appreciable amount of invasion, with
Matrigel penetrate still below the majority of epithelial-other and mesenchymal models.
Unlike binary EMT status, membership in the luminal papillary subcluster did predict
invasion, with Matrigel-coated transwell invasion significantly lower in this group of
models relative to the remainder of the panel (fig 20c).
Spheroid Assays Largely Recapitulate Transwell Invasion Results
Recent years have seen the development and widespread adoption of cancer
spheroid invasion assays, which are considered by some to be a more physiologically
relevant alternative to traditional, transwell-based invasion assays. Transwell assays
involve dissociation of two-dimensional cultured cells into a single cell suspension, with
cells then required to migrate through narrow and inflexible plastic pores. While these
systems allow for rapid examination of invasive properties, they may be biased towards
models that employ single cell, rather than collective, invasion. This possibility is
particularly concerning when considering EMT, as highly mesenchymal cells exhibit a
higher propensity for single cell motility184. Spheroid assays lack the constrictions of a
plastic based scaffold, relying instead on three-dimensional ECM scaffolds. They are
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therefore permissive of both single cell and collective invasion, making them more
versatile models of cancer cell motility.
In order to confirm patterns of Matrigel invasion obtained using coated
transwells, I generated spheroids from six cell line models- two luminal papillary, two
epithelial-other, and two mesenchymal- and embedded them in three-dimensional
Matrigel domes. As was observed in the transwell models, luminal papillary cell lines
exhibited minimal if any Matrigel invasion. Neither RT112 nor UMUC6 exhibited any
invasion in Matrigel domes, with all spheres exhibiting well defined edges and no
disseminated cells after 96 hours (fig 21a). Results in epithelial-other cell lines were
more mixed. SCABER spheres were highly invasive, producing pronounced,
multicellular projections into the surrounding matrix. UMUC9, which invades Matrigel in
transwell assays, behaved similarly to the luminal papillary models, failing to invade
during the 96-hour duration of the assay (fig 21b). Mesenchymal models were
consistently invasive, with UMUC3 spheres engaging in single cell dispersion and T24
spheres forming invasive, multicellular strands (fig 21c).
It is interesting to note that rather than underestimating the invasive
characteristics of certain models, as might be expected in situations that limit collective
invasion, transwell assays appear to be more permissive to invasion than sphere
assays. Neither UMUC6 nor UMUC9, both of which successfully invaded in the
transwell format (fig 20b), produced any single cell or collective invasion events during
the course of the spheroid assay(fig 21a,b). The reason for this discrepancy is
unknown, but may have to do with the absence of a chemo-attractant gradient in the
spheroid systems. Diffusion of growth factors from the lower transwell chamber
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Figure 21 Luminal Papillary models fail to invade in spheroid assays. Spheroid invasion
assay results recapitulate patterns observed in transwell assays with (A) luminal papillary
models RT112 and UMUC6 failing to invade over the course of the 96 hour assay. (B)
Epithelial-other models were partially invasive with SCABER but not UMUC9 invading Matrigel.
(C) Both mesenchymal UMUC3 and T24 were invasive. (D) Luminal papillary RT112 was
capable of degrading Matrigel despite failing to invade.
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stimulates invasion in the transwell assay, while sphere assays lack any such
directional cue. The addition of a particular growth factor stimulus using a microfluidics
system or some other mechanism could help explore this possibility.
Another interesting observation is the apparent uncoupling of matrix degradation
and invasion in RT112 cells. One of the main hurdles that must be overcome in
invasion is breakdown of surrounding matrix at least enough to enable nuclear
translocation through gaps in the ECM185. However, while RT112 invades effectively in
neither the transwell (fig 20b) nor the spheroid assay (fig 21a), it does appear to
breakdown Matrigel. By the end of the 96 hour assay, a minority of RT112 spheroids
exhibited areas of Matrigel degradation at the cell-ECM border (fig 21d). This
phenomenon was not associated with any changes in invasion, as these spheres
exhibited the same, uniform borders as other, non-degradative RT112 spheres. This
result suggests that other factors, beyond matrix degradation, limit invasion in RT112
and possible other luminal papillary cell lines.
While the sphere invasion assays did not yield results identical to those obtained
in transwells, they did largely recapitulate the trends observed in the larger screen.
Neither luminal papillary model exhibited invasive behavior over the 96 hour length of
the assay, while three of four epithelial-other and mesenchymal models were invasive.
When taken together, the results of the transwell and sphere invasion assays suggest
that luminal papillary subcluster membership, rather than a binary EMT-status, is
predictive of invasion in bladder cancer models.
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Invasion within the Epithelial Cluster Correlates with Partial EMT
Given the significantly lower invasive capacity exhibited by the luminal papillary
models, I sought to explore what made these cell lines different from the other, more
invasive models in the epithelial cluster. I again employed the IPA Upstream
Regulators function, this time excluding the mesenchymal models and directly
comparing gene expression patterns in luminal papillary and epithelial-other cell lines.
Networks activated in the luminal papillary subcluster were associated with a more
luminal phenotype, including estrogen associated gene expression and the PPARG
binding protein, PPARGC1A, though not PPARG itself (fig 22a). This finding is
consistent with the classifier subtype assignments. All members of the luminal papillary
subcluster are assigned to the luminal subtype, while the remainder of the epithelial
clade contains a mix of epithelial basal and luminal models (table 1 and fig 19a). The
association between the luminal subtype and less invasive disease7 may partially
explain the more indolent behavior of these models.
More interesting were the activated networks in the epithelial-other cell lines,
many of which were associated with EMT including TGFB1, TWIST1, TWIST2, and
SNAI1 (fig 22b). This outcome suggests that despite their presence in the epithelial
clade, these models exhibit gene expression patterns indicative of EMT. As noted
previously, the epithelial clade cells exhibit downregulation of EMT associated networks
relative to the EMT marker high mesenchymal cluster (fig 19c). In comparison to these
fibroblastic models, members of the epithelial cluster are highly epithelial. However,
EMT consists of a spectrum of partial states in which cells express elements of both the
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Figure 22 Epithelial-Other models exhibit a partial EMT characterized by SNAI1
expression. (A) IPA Upstream Regulator analysis of the luminal papillary subcluster revealed
enrichment for luminal regulators relative to the epithelial-other cell lines. (B) Relative to the
luminal papillary subcluster, epithelial-other models are enriched activation of EMT regulators
including TGFB1 and EMT transcription factors. (C) Epithelial-other cell lines exhibit enrichment
for epithelial marker CDH1 and mesenchymal marker SNAI1, but not mesenchymal marker
ZEB1
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epithelial and mesenchymal program66. Thus models in a partial EMT state could
reside within the larger epithelial clade, alongside more differentiated epithelial models.
Previous work in models of breast cancer has identified SNAI1 (Snail) as a
mediator of partial EMT, with ZEB1 thought to drive a more complete EMT 127. I
examined mRNA expression of these markers as well as the epithelial marker CDH1
(e-cadherin) in the luminal papillary, epithelial-other, and mesenchymal groupings.
Epithelial-other cells exhibit comparably high levels of CDH1, and comparably low
levels of ZEB1 to the luminal papillary models, suggesting both sets of cell lines are
epithelial (fig 22c). However, epithelial-other cells express significantly higher levels of
SNAI1 mRNA than the luminal papillary cell lines (fig 22c). This expression is
comparable to that seen in the mesenchymal cells. Cumulatively, these results suggest
that the epithelial-other cell lines occupy a partial EMT state, which is characterized by
activity of both epithelial and mesenchymal transcriptional networks. Cumulatively,
these results suggest that EMT, either complete (mesenchymal models) or partial
(epithelial-other models) does correlated with invasion in bladder cancer models. By
contrast, a highly epithelial state (luminal papillary models) is associated with significant
reductions in invasion capacity.
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CHAPTER 6
CONCLUSION AND FUTURE DIRECTIONS
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Src is Upregulated in Luminal Bladder Cancer and AZD0530 Inhibits Luminal Motility:
True, True, Unrelated
Earlier work suggested that Src expression is downregulated during disease
progression in bladder cancer13. However, I found that Src levels are elevated in
luminal tumors, which are themselves enriched among lower stage disease. Through
analysis of expression in multiple publicly available datasets, my work demonstrates
that Src is upregulated at the mRNA and protein levels in luminal relative to basal
bladder tumors. Phospho-Y416 Src, a marker of Src and SFK activation, is also
enriched in luminal cancers. These results demonstrated that, rather than being
downregulated as bladder tumors become more invasive, the inverse correlation
between Src and invasion is driven by increased Src expression among the bladder
cancer subtype more prevalent in lower stage disease. Based on this finding, I
hypothesized that Src drives invasion in luminal bladder cancer.
Src inhibition with AZD0530 had comparable cell signaling effects in
representative luminal and basal models, including ablation of Src target
phosphorylation and disruption of focal adhesion formation. Despite these similarities,
there were strikingly different effects on migratory phenotypes. Basal cell lines retain
substrate adherence when exposed to AZD0530. Their motility is either unaffected by
AZD0530, or, in certain instances, significantly increased by exposure to the inhibitor.
These results are in line with previous studies that suggested Src acts as a metastasis
suppressor in bladder cancer13,14. Luminal models, by contrast, were exquisitely
sensitive to the anti-motility effects of AZD0530. Drug treatment severely impaired
substrate attachment, a prerequisite for Src-driven motility, and significantly inhibited
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migration and invasion in nearly all cell lines and substrates tested. When viewed
alongside Src’s enrichment in luminal patient samples, these results suggested Src
behaves in a canonical, metastasis-promoting fashion in luminal cancers, while acting
in a non-canonical, motility-disrupting manner in basal cancers.
SFK inhibitors, including AZD0530, have affinity for a variety of kinase targets
outside of the Src family43,44. To validate Src as the phenotypically relevant target of
AZD0530 in luminal bladder cancer, I genetically ablated Src in UMUC6 cells using
CRISPR Cas9. While Src KO phenocopied AZD0530’s cell signaling effects, loss of Src
increased, rather than decreased, migration in UMUC6. Additionally, Src KO clones
remained sensitive to AZD0530. These results suggested that, as is the case in basal
cell lines, Src disruption in luminal models increases motility, and the anti-motility
effects of AZD0530 are driven by off-target activity.
AZD0530 directly inhibits TGFBR144 and TGF-beta responsive genes are
downregulated in UMUC6 following AZD0530 treatment. However, TGFBR1 inhibitor
galunisertib failed to replicate the AZD0530 phenotype alone or in combination with
bosutinib, a SFK inhibitor that does not disrupt TGF-beta signaling44. It is worth stating
that only a single dose of Bosutinib was used in this study. While kinase inhibitor
profiling44 and my own experiments suggest that the compound does not inhibit TGFbeta signaling, I cannot rule out the possibility that higher doses of bosutinib would
inhibit TGFBR1. Additional experiments are needed to explore this possibility.
Notably, UMUC6 was insensitive to bosutinib, demonstrating that inhibition of
other SFKs is not responsible for the differences between Src KO and AZD0530
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treatment in this model. Bosutinib had only limited activity in luminal RT112 cells,
further supporting the notion that AZD0530’s relevant target is not an SFK.
Kinobead Identifies ADCK3 as a Possible Target of AZD0530
A previous study has examined the activity of both AZD0530 and bosutinib
against a broad portion of the kinome using the Kinobead platform 44. By comparing the
Kinobead-derived profiles of AZD0530 and bosutinib, I sought to identify candidate
kinase targets of AZD0530 in luminal bladder cancer. Only one target, the
mitochondrial kinase ADCK3, was enriched among luminal tumors across multiple
patient cohorts. While little is known about the specific impact ADKC3 might have on
cell motility, there is an increasing appreciation of the role played by mitochondria in
tumor cell invasion and metastasis. A growing body of evidence supports the notion
that dysregulation of mitochondrial dynamics is an important driver of dissemination. It
is hypothesized that by relocalizing mitochondria, tumor cells are able support the
energy needs of a variety of motility associated processes including lamellipodia
formation, cytoskeletal remodeling, and focal adhesion turnover179
Early work examining the role of mitochondria in cancer cell motility was
performed by Zhao et al. 2013, which studied the dynamics between mitochondrial
fission and fusion in relation to invasion. They found siRNA mediated knockdown of the
fission promoting factor, DRP1, decreased migration and invasion in MDA-MB-231 and
MDA-MB-436 cells186. These decreases were associated with re-localization of
mitochondria away from the lamellipodia. Furthermore, chemical disruption of
mitochondrial ATP synthesis through treatment with CCCP or Oligomycin A severely
limited lamellipodia formation, migration, and invasion186. These results suggested that
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both mitochondrial localization and mitochondrial ATP production are important to
cancer cell motility.
Interference with mitochondrial function also inhibits cancer cell invasion in other
systems. Rivadeneira et al. 2015 studied the role played by a mitochondria-localized
pool of the protein survivin. They found mitochondrial survivin promoted both cellular
respiration and redistribution of mitochondria to the cortical cytoskeleton, which in turn
drove increased lamellipodia membrane ruffling, focal adhesion turnover, and invasion.
Disruption of mitochondrial trafficking, achieved by siRNA mediated knockdown of
survivin in PC3 prostate cancer cells, yielded decreased migration in scratch assays as
well as decreased Matrigel invasion in transwell assays187. Rescue experiments with
mitochondria-targeted survivin partially mitigated these effects. Additionally, expression
of mitochondria-targeted survivin was able to promote motility, with increased invasion
and liver metastasis observed in MCF-7 breast cancer cells187.
Additional lines of evidence further support the notion that mitochondria drive
metastasis in vivo. Chuang et al. 2021 identified increased sensitivity to mitochondrial
disruption as a defining characteristic of cell lines derived from metastases, relative to
primary tumor-derived cell lines, in the KRASG12D; Trp53KO lung adenocarcinoma
GEMM. When metastasis-derived lines were re-implanted subcutaneously, inhibition of
mitochondrial activity through treatment with phenformin or high-dose doxycycline had
limited effects on primary tumor growth, but significantly impaired dissemination 188.
Evidence suggests that disruption of ADCK3 activity impairs mitochondrial
function, which in turn could limit cell motility. ADCK3 is involved in production of Coenzyme Q177, which facilitates electron transfer among the protein complexes within the
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mitochondrial election transport chain, enabling cellular respiration189. Mutations in
ADCK3 have been identified in patients with recessive ataxias, neurodegenerative
disorders that impact the brain and peripheral nervous system, which are associated
with defects in mitochondrial function190.
The links between mitochondria and tumor invasion, combined with ADCK3’s
role in enabling cellular respiration, support a case for the protein as AZD0530’s
phenotypically relevant target. By inhibiting ADCK3, AZD0530 may disrupt
mitochondrial ATP production, depriving luminal bladder cancer cell lines of the energy
needed to migrate and invade. This hypothesis could be tested through a series of
experiments examining the impact of AZD0530 on mitochondria and through RNAinterference based disruption of ADCK3 activity. Given the role of ADCK3 in producing
Co-enzyme Q, rates of cellular respiration could be measured in AZD0530-senstive
models following drug treatment. The impact of AZD0530 on mitochondrial localization,
particularly to the lamellipodia, would also be warranted. If AZD0530 were found to
disrupt mitochondrial function, it would make a compelling argument for ADCK3
inhibition as the mechanism of action for this compound in luminal bladder cancer.
Direct examination of ADCK3’s importance to motility could be determined using siRNA
or shRNA against ADCK3 in luminal cell lines, followed by transwell assays to measure
changes in migration and invasion.
Limitations of Kinobead: The Possibility of Targets Beyond ADCK3
Alternatively, the absence of evidence directly linking ADCK3 to cell motility, and
the lack of ADCK3 upregulation in luminal cell lines, may indicate that it is not a
relevant target of AZD0530. While the Kinobead platform is a powerful tool for target
119

identification, there are inherent limitations to the technology which prevent
examination of all possible targets. Kinobead is a cell lysate-based assay, which allows
for target affinity screening in a more complex and physiologically relevant system than
many other in vitro assays44. However, kinase targets must both be expressed and in
an active state in the cells used in order to be capture by the screen. Lysate pooling
from multiple cancer cell lines partially mitigates this limitation44, but it leaves open the
possibility that AZD0530’s relevant target is not included among the kinases examined.
Additionally, some kinases are incompatible with Kinobead for unknown reasons 44,
yielding another gap in kinome coverage.
The platform does not include non-kinase targets, like g-protein coupled
receptors, which some kinase inhibitors may interact with44. Compounds designed to
disrupt kinase activity can also interact with other, unexpected cell components. For
example, recent attention has been given to the previously unexamined microtubule
disrupting activity of some kinase inhibitors, which drive a portion or all of these
compounds’ anti-cancer activity in certain systems191. Effects like these and activity
against other, non-traditional targets are difficult to identify with normal screening
methods, necessitating novel and creative approaches.
Additional experiments could help to identify the target or targets responsible for
the anti-migration and anti-invasion effects of AZD0530 in luminal bladder. Comparison
of AZD0530 and bosutinib, which have overlapping target profiles but very different
effects in luminal cell lines, can be further leveraged in this effort. Examining the impact
of both compounds on the phospho-proteome by RPPA or mass spectrometry could
help identify new candidates while filtering out the effects of shared, non-pertinent
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targets. A similar strategy could be applied to a high content imaging-based phenotype
screen, which can help identify unusual activity, like microtubule disruption, that may be
missed by cell signaling based approaches191,192.
AZD0530 as an Anti-Progression Agent in Bladder Cancer
While the relevant target of AZD0530 remains unclear, my data supports the use
of this compound as an anti-progression agent in luminal bladder cancer. Treatment
with AZD0530 significantly inhibited luminal cell line migration and invasion in the vast
majority of models. Luminal cancers are over-represented among NMIBC patients7,
who are best positioned to benefit from an anti-invasive as anti-progressive therapeutic
strategy. The greatest clinical concern in NMIBC is local invasion, which AZD0530 may
disrupt, rather than outgrowth of pre-existing metastatic disease, a process on which
AZD0530 is likely to have little effect. Treatment with AZD0530 could delay or prevent
the need for more aggressive interventions, like radical cystectomy or cisplatin-based
chemotherapy, thus preserving a higher quality of life in these patients.
An argument could be made that absence of a defined mechanism of action,
even with promising preclinical data, would hinder further development of AZD0530 in
bladder cancer. Failure to identify relevant targets is a common problem in oncology
drug development, which may drive the high rates of clinical trial failure. By employing
a CRISPR-based knockout approach, Lin et al. 2019 sought to validate the drug targets
of oncology agents already in clinical testing. The authors found multiple instances in
which compound anti-cancer activity was wholly unrelated to the intended target.
Target-KO cells exhibited no decreases in cell proliferation and remained sensitive to
the agents, even in the absence of the purported target 193. While these compounds
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may still be effective by acting on unintended proteins, the authors noted that the
inability to accurately identify a mechanism of action severely hampers predictive
biomarker selection193. However, the correlation of AZD0530 sensitivity with luminal
bladder cancer sidesteps this problem. By using luminal markers to identify patients
likely to respond to AZD0530, the compound can still be used for biomarker driven
clinical studies, even while the exact mechanism of action remains unclear. This
approach allows for further testing on AZD0530 to take place in parallel with efforts to
identify its relevant target.
Such a strategy has been proposed for another SFK inhibitor, dasatinib, in
diffuse large B cell lymphoma (DLBCL). Through a drug repurposing screen, Scuoppo
and colleagues identified dasatinib as a promising candidate for the treatment of
DLBCL. Activity was likely unrelated to Src, as dasatinib was active in models
unaffected by another agent that inhibits Src, ibrutinib. The exact mechanism by which
dasatinib exerted its anti-cancer activity in DLBCL remains unknown. However, the
authors found resistance to be associated with PTEN mutations, providing a biomarker
with which to screen patients in lieu of drug target expression or alteration status 194. In
the case of AZD0530 and bladder cancer, expression of luminal markers like KRT20 or
GATA3 by immunohistochemistry could serve the same purpose, with high levels being
a pre-requisite for treatment.
While there is a path forward for AZD0530 in bladder cancer, more research is
required before this agent should be moved forward into clinical trials. Future studies to
validate AZD0530’s anti-migratory effects are needed. Activity must be confirmed in
physiologically relevant animal models of bladder cancer, such as orthotopic xenografts
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of luminal cell lines. Experiments in luminal GEMMs currently in development, or
recently established luminal marker positive patient-derived organoid lines180, would
also be of value. If such preclinical studies provide evidence supporting AZD0530’s
efficacy, novel clinical trials, similar in design to the Hahn et al. 2016 neoadjuvant
dasatinib study, would be warranted102. Such a trial could examine the impact of perioperative AZD0530 on rates of progression in high risk NMIBC patients designated for
cystectomy, with disease stage at surgery as a measure of drug efficacy. In conclusion,
AZD0530 is a promising candidate for anti-invasive therapy in luminal bladder cancer,
worthy of further preclinical, and possibly clinical, development.
Future Directions: What drives increased basal motility following AZD0530 treatment?
An outstanding question generated by this research is how AZD0530 treatment
drives increased motility in certain models of basal cancer. One plausible explanation
lies in earlier studies, which proposed a model where by Src limits cell movement by
activating the metastasis suppressor, RhoGDI213 and by antagonizing the activity of
metastasis promoter, Cav-114. In such a signaling network, inhibiting Src with AZD0530
would promote an aggressive, invasive phenotype. The findings of this study are not
incompatible with the RhoGDI2/Cav-1 hypothesis, which could explain the
phenomenon observed here. However, a broader examination of the cell migration
literature brings another possibility into focus.
Basal cells may readily shift from the classically studied adhesion-based motility,
in which Src is heavily implicated, to “amoeboid” motility, which is thought to be Src
independent. Adhesion based motility requires dynamic interactions between the actin
cytoskeleton and ECM, mediated by Src containing focal adhesion complexes, and
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peri-cellular proteolysis, also regulated by Src29,47,184. It encompasses the
mesenchymal motility of fibroblasts and EMT cancer cells, as well as the collective
motility of epithelial cells, provided they meet the noted criteria 184. Amoeboid motility by
contrast is largely adhesion and degradation independent. It involves RhoA/ROCK
induced contractility, which causes membrane blebbing that allows cells to flow through
complex matrices, moving at higher speeds than mesenchymal cells 184. Amoeboid
motility has been observed in numerous cancer models, with cells able to switch
between motility modes through a mesenchymal to amoeboid transition (MAT)184,
named as such because the models in which it has been historically observed are
generally exhibit a fibroblastic, mesenchymal phenotype195–197.
Independence from Src signaling is one of the hallmarks of amoeboid motility.
Carragher et al. 2006 found that HT1080 sarcoma cells normally engage in adhesive
motility, and exhibit decreased migration through collagen gels when treated with PP2
and another SFK inhibitor, ALLN. However, when forced to undergo MAT by treatment
with a protease inhibitor, HT1080 became insensitive to SFK inhibition, and actually
migrated more rapidly upon exposure to PP2 and ALLN195. The same study also found
that mesenchymal BE cells were sensitive to the anti-migratory effects of PP2 while
another, amoeboid model, LS174T, was wholly unaffected by PP2 treatment 195.
Later studies demonstrated that SFK inhibitors are able to induce MAT. Ahn et
al. 2012 found that overexpression of NEDD9 induced a highly motile, mesenchymal
phenotype in WM1362 melanoma cells. SFK inhibition with dasatinib forced these cells
to undergo MAT, resulting in increased collagen gel invasion. Identical results were
obtained with parental SKMEL28 cells196. Work in A375 cells also suggested that SFK
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inhibition drives MAT. Treatment of this model with dasatinib induced de-adhesion to
fibronectin coated coverslips and bleb formation, both hallmarks of MAT 197.
Additionally, when forced to utilize amoeboid locomotion due to confinement in a
closed, low adhesion device, A375s assumed a blebbed phenotype and became
insensitive to dasatinib197.
While MAT is a plausible explanation for the basal AZD0530 phenotype, my data
provides evidence both for and against the hypothesis. Basal models are broadly
resistant to AZD0530, with certain cell lines migrating and invading more when treated.
These results are consistent with a MAT-mediated resistance model. However, these
data were generated using transwell assays, which require 2D migration along the
chamber surface in addition to pore translocation, which could be considered more 3D
in nature. Some argue that true amoeboid motility can only occur in confined, 3D
environments198 and studies linking Src inhibition to MAT were performed in systems
that met those criteria195–197. However, others dispute that a 3D environment is a
prerequisite for all types of amoeboid motility199. Additionally, unlike sensitive, luminal
models, basal cell lines retain substrate adhesion when treated with AZD0530,
exhibiting a phenotype more consistent with adhesive than amoeboid motility.
It is possible that upon entry into the confining environment of the transwell pore,
AZD0530 treated basal cell lines adopt an amoeboid morphology that is not seen in 2D
culture conditions. Alternatively, like EMT, MAT may consist of a spectrum of cell
states200, with basal cells able to adopt components of the amoeboid program while
retaining some mesenchymal features. Further studies are needed to explore these
hypotheses. Live cell imaging of basal cell lines migrating through 3D collagen cells
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could be used to examine the frequency of MAT upon SFK inhibition. Treatments
designed to inhibit amoeboid motility would complement these experiments. Disruption
of the RhoA/ROCK signaling axis, which drives the contraction-induced blebbing of
amoeboid cells184, could also be used to confirm the reliance of basal models on an
amoeboid program.
Future Directions: What is the mechanism underlying the UMUC6 Src KO Phenotype?
The most exciting and surprising finding of this study was the increased
migration observed in UMUC6 cells following Src KO. The exact mechanism driving
this phenomenon remains unknown, and requires additional experimentation to
elucidate. Possible explanations are similar to those for the basal AZD0530 phenotype.
Src loss may limit the activity of RhoGDI2 or allow increased activation of a motility
inducing Cav-1 axis. Alternatively, loss of Src may promote KO clone migration by
activating a non-adhesive cell motility program.
There is, however, a key difference between the luminal Src KO and basal
AZD0530 phenotypes, namely the timescale at which they are observed. Basal cell
lines exhibit increased motility following acute Src disruption with a chemical inhibitor.
KO induced, long-term disruption of Src in UMUC6 had the same effect. By contrast,
acute treatment of parental UMUC6 cells with bosutinib failed to either inhibit or
promote motility. This distinction suggests larger changes than simple shifts in
RhoGDI2 and Cav-1 activity are at play in UMUC6.
Transition to an amoeboid phenotype however, is potentially reconcilable with
the need for longer term loss of Src signaling. The switch between an adhesive mode
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of locomotion to one characterized by amoeboid blebbing has been observed and
studied in mesenchymal cancer models, such as sarcoma195 and melanoma196 cell
lines. Basal tumors exhibit gene expression indicative of partial or full EMT4,5. Basal
models may therefore be primed to undergo MAT, able to adopt an amoeboid
phenotype following short term, chemical-mediated Src inhibition. Luminal UMUC6, by
contrast, is highly epithelial. RNA-Seq based hierarchical cluster of our bladder cancer
cell line panel places UMUC6 in a highly epithelial, luminal papillary clade. If Src loss
does drive shifts to amoeboid motility in UMUC6, an epithelial to amoeboid rather than
mesenchymal to amoeboid transition, extended disruption of Src signaling
accomplished by a genetic ablation, rather than acute loss through short term inhibitor
treatment, may be required. In short, adaptation to Src loss may take longer in luminal
than basal models. While this hypothesis is plausible, it requires additional
experimentation to be adequately tested. An examination of cell migration in UMUC6
knockout clones via live cell imaging in 3D collagen gels would confirm amoeboid
motility. Additionally, chronic exposure of UMUC6 to bosutinib could be used to
examine the dichotomy between acute and chronic Src disruption.
Another explanation for the discrepancy between the increased migration of Src
KO UMUC6 cells and the lack of effect seen when parental UMUC6 is exposed to
bosutinib may lie in the intrinsic differences between chemical inhibition and total
genetic ablation. Kinase-independent effects of Src KO may drive the increased motility
seen in these cells. Kinase inhibitors, like bosutinib, disrupt phosphorylation of
downstream substrates, while leaving the target protein itself intact. KO, by contrast,
completely eliminates a target protein, disrupting both kinase signaling and any non-
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kinase processes, like serving as a scaffold to facilitate other protein-protein
interactions. Evidence suggests Src may have kinase independent functions, which
would be affected by CRISPR-Cas9 mediated KO, but not drug treatment. Kaplan et al.
1995 found that a kinase-deficient variant of Src was able to restore cell spreading in
Src-/- fibroblasts just as efficiently as wildtype Src32. Kinase deficient Src is also able to
mitigate the bone defects observed in the Src-/- mouse model. Expression of a kinasedeficient Src transgene significantly increased bone volumes in Src-/- mice, while also
improving measures of bone resorption by osteoclasts201.
The hypothesis that Src inhibits motility in UMUC6 through non-kinase
associated activity can be tested through more precise genetic manipulation of Src, as
well as rescue experiments in the Src KO models. Mutation of the Src kinase domain,
rendering it ineffective while retaining the remainder of the protein, is a better
approximation of kinase inhibition than Src KO. Src kinase domain mutation, achieved
by CRISPR Cas9 paired with a mutant homologous repair template, could be used to
compare the kinase and kinase independent roles of Src in bladder cancer motility.
Rescue in Src KO UMUC6 cells, wherein the effects of transfection with wildtype and
kinase deficient Src constructs on migration are measured, would also serve to clarify
the kinase and non-kinase roles of Src in this context.
An additional rationale for the UMUC6 Src KO phenotype must also be
considered. Rather than inducing an amoeboid adaptation response, Src loss may
present a selection event in these cells. UMUC6 is among a subset of bladder cancer
cell lines dependent on EGFR signaling for proliferation202. Src signals downstream of
EGFR8 and also reenforces EGFR signaling by directly phosphorylating the receptor 39.
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Bulk population UMUC6 cells are sensitive to growth inhibition by EGFR inhibitors
erlotinib202 and gefitinib (unpublished observations), as well as the EGFR-specific
neutralizing antibody, cetuximab202. It stands to reason that disruption of Src signaling,
through carry-on effects on the EGFR network, would select against the majority of
“typical” UMUC6 cells in favor of clones with properties that are not generalizable to the
bulk population. In such a scenario, the increased migration seen in Src KO UMUC6
clones may not be due to Src loss per say, but rather the unique characteristics of
UMUC6 subpopulations that can proliferate and survive in the absence of Srcassociated EGFR signaling. Proliferation assays provide some support to this
interpretation. Parental UMUC6 is one of the few bladder cancer models sensitive to
the antiproliferative effects of AZD0530. However, the target promiscuity of AZD0530
makes it impossible to definitively attribute this phenotype to Src inhibition. Short term
genetic disruption via siRNA or inducible shRNA is required to validate Src as an
antiproliferative target in UMUC6. Rescue experiments, wherein the ability of wildtype
Src to restore normal migration behavior in Src KO cells would also be of value.
Additionally, confirmation of EGFR independence in UMUC6 Src KO models by
proliferation assay with EGFR targeted agents would support this hypothesis.
Alternatively, validation of the effects of Src KO in EGFR-independent luminal models,
like RT112, would serve to confirm that the Src KO results are broadly generalizable
rather than an artifact of UMU6’s dependence on EGFR.
EMT Correlates with Invasion in Bladder Cancer Models
The literature provides conflicting evidence on the importance of EMT for cancer
invasion and metastasis. Additionally, research on EMT in bladder cancer is quite
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limited. I therefore sought to explore the relationship between EMT and invasion in a
panel of bladder cancer cell lines. Because of the correlation between EMT and
bladder cancer subtype, I first examined the subtype status of our models. Researchers
in my lab developed a gene expression classifier capable of differentiating between
basal and luminal bladder tumors. When applied to our lab’s 30 cell line panel, this
classifier generated subtype calls with high confidence in the majority of cases.
However, I observed a loss of epithelial-basal marker expression among many of the
basal-called models, which correlated with strong induction of EMT. Additionally, many
of the luminal models co-expressed luminal and basal markers. These observations are
consistent with results obtained by other researchers, who found a progressive shift
towards a basal marker profile in luminal tumor derived organoid models, which
reversed upon implantation into murine hosts180.
Following hierarchical clustering of the cell lines, two main clades formed which
were differentiated mainly by EMT status. The first cluster consisted almost entirely of
basal called models, and was enriched for EMT marker expression. The second cluster
contained a mixture of epithelial basal and epithelial luminal called cell lines. Within this
second, epithelial clade was a subcluster enriched for cell lines with FGFR3 activating
alterations. Given the association between FGFR3 alterations and luminal papillary
bladder tumors, I designated this group the luminal papillary subcluster.
There was no difference in Matrigel transwell invasion between the epithelial and
mesenchymal clusters, which suggests binary EMT classification does not predict
invasive capacity. However, the majority of cell lines from the luminal papillary
subcluster failed to invade Matrigel. This result is consistent with clinical trends
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observed in humans, where luminal papillary characteristics are enriched in lower stage
MIBC6. When compared to the rest of the cell line panel, luminal papillary models do
exhibit significantly reduced invasion, making subcluster membership a better predictor
of invasion that binary EMT status. Spheroid invasion assays of representative
mesenchymal, luminal papillary, and epithelial-other (epithelial clade cell lines outside
of the luminal papillary subcluster) followed the same trends as the transwell assays.
In an effort to understand the luminal papillary phenotype, I compared that
subcluster to the remainder of the epithelial cluster. Relative to the luminal papillary
models, epithelial-other cell lines exhibit a partial EMT phenotype, consisting of coexpression of EMT (SNAI1 or Snail) and epithelial (CDH1 or e-cadherin) markers.
Given the association between EMT and invasion, this result suggests that EMT could
be behind the differences in invasion among sections of the epithelial cluster.
While there were not significant differences in the invasive capacity when the
cell lines were categorized by binary EMT status, my data still support a role for EMT in
bladder cancer invasion. Early works conceptualized epithelial and mesenchymal
phenotypes as distinct, with EMT and MET allowing full shifts from one state to
another. We now understand that EMT encompasses a continuum of intermediate
states which exhibit co-expression of markers and have phenotypes that include
elements of both cellular programs. Bladder cancer cell lines exhibit highly epithelial,
hybrid, and highly mesenchymal phenotypes. The highly epithelial luminal papillary
subcluster models failed to invade Matrigel in both transwell and spheroid invasion
assays. EMT marker positive epithelial-other and mesenchymal models by contrast
were both highly invasive.
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These data, though correlative, support the hypothesis that EMT is a driver of
invasion in bladder cancer. Models with EMT-associated gene expression (epithelial
other and mesenchymal) were invasive while those without it (luminal papillary) were
not. This result is in line with previous clinical studies, which have found EMT marker
expression to be associated with more invasive and aggressive disease variants in
both MIBC4–6 and NMIBC147. Though additional mechanistic studies to modulate EMT
in each set of models are needed to validate these findings, my results unambiguously
support an EMT-mediated model of invasion in BC.
Partial and Full EMT Models are Comparably Invasive: Implications for Metastasis
My data also suggest that partial and full EMT confer similar invasive capacity.
Partial EMT epithelial-other and full EMT mesenchymal models were comparably
invasive. Rather than producing a continuum of invasion phenotypes, there appears to
be a diminishing return on invasion with further shifts towards a mesenchymal state.
This outcome is particularly interesting when considered alongside data that show
partial, but not full EMT, promotes a stem-like phenotype127. Completion of the
metastatic cascade requires cells to have both motility-promoting and stem-like
properties, allowing for travel to secondary sites and outgrowth once there 125. Rather
than a trade-off between invasion and stemness, partial EMT may provide the same
motility advantages as a mesenchymal cell state with an increase in tumorgenicity.
However, additional studies are needed to confirm the stemness advantage of
partial EMT cells in bladder cancer. Colony forming assays and limiting-dilution
tumorigenicity assays in murine hosts would be able to compare the stem-like
phenotypes of the epithelial-other and mesenchymal cell lines. It would also be worth
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exploring these characteristics in luminal papillary cell lines, which would theoretically
have lower measures of stemness than epithelial-other models due to their non-EMT
phenotype.
Future Directions: What Induces the Partial EMT State in Some Epithelial Models?
The driver of partial EMT in portions of the epithelial cluster still needs to be
explored. One attractive candidate is the EMT transcription factor, Snail (SNAI1).
Unlike members of the Zeb family, which induce a more fully mesenchymal phenotype,
Snail has been shown to promote an intermediate EMT state which preserves epithelial
characteristics127. Snail is also upregulated in the EMT positive portion of the epithelial
cluster relative to the EMT low, luminal papillary models. Expression of Snail in the
partial EMT epithelial cluster cell lines is comparable to that seen in the mesenchymal
cluster. Snail also promotes dissemination in spontaneous metastasis models of the
mesenchymal cluster cell lines157, and may have similar activity in more epithelial
models.
It is possible that Snail drives EMT, thereby promoting invasion and metastasis
in epithelial bladder cancer cell lines. This hypothesis could be tested through shRNA
mediated knockdown or CRISPR-Cas9 mediated knockout of Snail, followed by an
examination of EMT markers and functional assessment of invasion. It is also possible
that a different transcription factor or factors drives EMT in these cell lines. EMT
transcription factor expression is often regulated at the protein level, and mRNA levels
are not always accurate surrogates of the activity of these proteins203. Other candidate
factors, including Slug (SNAI2), and Twist could also be examined if Snail modulation
fails to impact EMT or invasion.
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Future Directions: What Drives Invasion in Luminal Papillary Tumors?
An outstanding question posed by this work is how EMT-low luminal papillary
tumors invade. Luminal papillary cell lines broadly failed to penetrate Matrigel in both
transwell and spheroid invasion assays. But while these tumors are less invasive in
patients, they do progress to muscle invasion in certain cases6. One hypothesis is that
these cancers employ EMT, but do so less efficiently. Alternatively, they may require
the assistance of stromal cells, such as fibroblasts, which are absent in cell culture.
Previous studies have shown fibroblasts are able to induce EMT in bladder cancer cell
lines through release of soluble factors150,151, though evidence in luminal papillary
models in lacking. Further studies using patient samples could shed light on the
possibility of EMT or fibroblast-mediated invasion in luminal papillary cancers.
The most powerful evidence for EMT or fibroblast-mediated invasion in luminal
papillary cancers would be the identification of these cells in invasive cancers. While a
number of studies have use micro-array or RNA-sequencing to examine the gene
expression profiles of bladder tumors4–6, these methods lack the singe cell resolution
required to identify rare cell populations, like EMT positive cancer cells or fibroblasts in
largely epithelial tumors. Single cell RNA-seq, which has the capacity to characterize
individual cells, could be used to determine whether rare EMT tumor cells are present
in invasive luminal papillary tumors. The technology would also allow for more detailed
stromal cell profiling of invasive and non-invasive luminal papillary cancers, making it
possible to detect invasion promoting fibroblasts in these tumors.
Techniques that can couple marker expression and spatial localization would
also be of value, allow for profiling of cells at the invasive front. Recently developed
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spatial sequencing technologies, like the GeoMx204 and the Visium Spatial Gene
Expression205 platforms allow for the analysis of high numbers of RNA markers within
visually defined areas, combining expression information with tissue architecture.
These technologies would allow for the identification of EMT tumor cells actively
invading at the tumor edge, or fibroblasts and other stromal cell populations localized to
areas of invasion into the bladder wall. The presence of these cells at the invasive front
would provide strong evidence support either EMT or stromal-driven invasion as drivers
of progression in luminal bladder cancers.
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